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Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder that has no cure, 
no therapies to stop the disease progression, and limited palliative care options. As the 
6th leading cause of death in the United States, it is necessary to discover therapeutics 
which can alter disease progression to alleviate the burden on patients, caregivers, and 
healthcare systems. In the search of therapeutics for AD, dietary polyphenols have 
become the topic of research as epidemiological evidence suggests that exposure to 
dietary polyphenols, such as a Mediterranean diet, over one’s life, reduces the risk of 
dying from AD. Additionally, evidence from rodent models of AD suggests that dietary 
polyphenols can reduce the severity of cognitive decline and attenuate 
neuroinflammation, which is thought to be a contributing factor to disease progression. 
Because of these findings, several dietary polyphenols have entered the clinic in an 
attempt to elucidate their potential beneficial effects. For example, curcumin, from the 
curry spice turmeric (Curcuma longa), and resveratrol, a phytoalexin stilbene found in 
a variety of plants, have been investigated in AD disease populations in phase I and II 
clinical studies. However, these agents have only had moderate to little success which 
increases the demand for novel dietary polyphenols leads that may have potentially 
beneficial effects in the treatment of AD. Due to this demand, this dissertation 
investigates novel polyphenols and gut metabolites of dietary polyphenols from a 
variety of dietary sources for potential efficacy in a Caenorhabditis elegans (C. elegans) 
model of AD. This dissertation also employs molecular biology and mass spectrometry 
techniques to elucidate the potential mechanisms of action of select compounds found 
to be efficacious in a C. elegans model of AD. Finally, a polyphenol-enriched extract 
 
 
was evaluated in a murine model of AD for the potential to reduce neuroinflammation 
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SATEMENT OF THE PROBLEMS 
Alzheimer’s disease poses a substantial risk to human health, a risk that is growing 
steadily as the population ages. Nevertheless, few reliable treatments exist to slow the 
progression of, mitigate symptoms, or cure this disease. In recent years, dietary 
polyphenols have been evaluated for their therapeutic potential. These compounds 
have been shown to reduce inflammation, disaggregate amyloid deposits, and reduce 
hyperphosphorylated tau. In animal models of Alzheimer’s disease, polyphenols have 
shown to reverse the cognitive deficits associated with the disease. An emerging field 
in the area of polyphenol research is the potential therapeutic benefit of gut microbiota 
metabolites of polyphenols. Given the chemical nature of polyphenols, their 
penetration across the blood-brain barrier is limited. However, gut microbiota 
metabolites undergo several methylation, dehydroxylation and various other catabolic 
reactions which increases the likelihood of blood-brain barrier penetration due to 
reduced polarity and molecular weight. Herein, this dissertation describes the 
identification of potential therapeutics from dietary polyphenols and gut microbiota 
metabolism of these polyphenols, the mechanisms of action responsible for these 
natural products’ potentially beneficial effects, and the efficacy of one of these 






EFFICACY OF DIETARY POLYPHENOLS AND GUT METABOLITES IN A 
CAENHORBADITIS ELEGANS MODEL OF ALZHEIMER’S DISEASE AND 
INFLAMMATION 
 
Manuscript 1 appears as published: 
Isolation, identification, and biological evaluation of phenolic compounds from a 
traditional North American confectionary, maple sugar. Liu, Yougqiang. Rose, 
Kenneth N.; DaSilva, Nicholas A.; Johnson, Shelby L.; Seeram, Navindra P. (2017) 
Journal of Agricultural and food chemistry. 65, 4289-4295.   
 
Manuscript 2 appears as published: 
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Zhang, Lu; Wan, Chunpeng; Dain, Joel A.; Seeram, Navindra, Seeram P. (2016). 
Neurochemistry International. 100, 164-177.   
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Phenolic compounds isolated and identified from Amla (Phyllanthus emblica) juice 
powder and their antioxidant and neuroprotective activities. Rose, Kenneth N.; Wan, 
Chunpeng; Thomas, A; Seeram, Navindra P.; Ma, Hang. (2018). Natural Product 









Dietary polyphenols and gut microbial metabolites of dietary polyphenols offer a 
diverse and large library of compounds that are potentially beneficial for the treatment 
of neurodegenerative diseases, which potentially increases the likelihood of an 
effective compound to be discovered and exploited clinically. This also offers a 
significant scientific challenge. With such a vast library to search, there must be 
efficient methods of determining which compounds should be further investigated and 
which should be discarded as not relevant to the study. Herein, this chapter describes 
the use of wild-type and a transgenic C. elegans model, which expressed the human b-
amyloid3-42 gene, to evaluate polyphenols and gut microbial metabolites derived from 
a variety of plant sources.   
The sources of polyphenols and their gut microbial metabolites used in this chapter are 
from three plants that have been identified as being potentially beneficial for the 
treatment of neurodegenerative diseases. The first is a maple syrup as an standardized, 
phenolic-extract of maple syrup has recently been demonstrated to reduce 
neuroinflammation markers in human SH-SY5Y neuroblastomas and reduced the 
LPS-induced inflammation in murine BV-2 microglia.  
The second is an extract from the fruit of Punica granatum (Pomegranate) as previous 
work has demonstrated that the extract can attenuate hydrogen peroxide-induced 
toxicity in murine microglia BV-2. Furthermore, pomegranate ellagitannins are known 
to be the parent compound of the gut microbial metabolites urolithins. Previous 
research has identified that urolithin treatment increases the lifespan of CL4176 C. 
elegans and improves cellular respiration and induce mitophagy leading to overall 




The third is an extract from the fruit of Phyllanthus emblica (Amla or Indian 
Gooseberry) as it is commonly used in the Ayurvedic system of traditional medicine. 
The pure chemical constituents of the Indian Gooseberry plant are well known and 
have been described as antioxidants. As with the pomegranate extract, the amla extract 
contains ellagic acid and several ellagic acid derivates which are known to form 
urolithins upon ingestion. The extract of Indian Gooseberry has been identified as 
being potentially neuroprotective based on its antioxidant properties and its ability to 
reduced β-amyloid fibrillization.  
This chapter describes the investigation of these sources of natural products for their 
potentially efficacious effects involved treating C. elegans with the various 
compounds and extracts in their growth media and examining differences in survival 





Manuscripts 1 appears as published in the Journal of Agriculture and Food Chemistry. 
 
Isolation, identification, and biological evaluation of phenolic compounds from a 
traditional North American confectionary, maple sugar. Liu, Yougqiang. Rose, 
Kenneth N.; DaSilva, Nicholas A.; Johnson, Shelby L.; Seeram, Navindra P. (2017) 






Maple sap, collected from the sugar maple (Acer saccharum) tree, is boiled to produce 
the popular plant-derived sweetener, maple syrup, which can then be further 
evaporated to yield a traditional North American confectionery, maple sugar. 
Although maple sap and maple syrup have been previously studied, the phytochemical 
constituents of maple sugar are unknown. Herein, 30 phenolic compounds, 1−30, 
primarily lignans, were isolated and identified (by HRESIMS and NMR) from maple 
sugar. The isolates included the phenylpropanoid-based lignan tetramers 
(erythro,erythro)-4″,4‴-dihydroxy-3,3′,3″,3‴,5,5′-hexamethoxy-7,9′;7′,9-diepoxy-
4,8″;4′,8‴-bisoxy-8,8′-dineolignan-7″,7‴,9″,9‴-tetraol, 29, and (threo,erythro)-4″,4‴-
dihydroxy-3,3′,3″,3‴,5,5′-hexamethoxy-7,9′;7′,9-diepoxy-4,8″;4′,8‴-bisoxy-8,8′-
dineolignan-7″,7‴,9″,9‴-tetraol, 30, neither of which have been identified from maple 
sap or maple syrup before. Twenty of the isolates (selected on the basis of sample 
quantity available) were evaluated for their potential biological effects against 
lipopolysaccharide-induced inflammation in BV-2 microglia in vitro and juglone-
induced oxidative stress in Caenorhabditis elegans in vivo. The current study 
increases scientific knowledge of possible bioactive compounds present in maple-






Maple syrup and maple sugar are traditional North American sweeteners commercially 
produced only in eastern North America, predominantly in the province of Quebec in 
Canada.  They are obtained by boiling the sap collected from the sugar maple (Acer 
saccharum) species which is endemic to this part of the world. Maple syrup is obtained 
by boiling sap (approx. 40 L sap yields 1 L of syrup) and on further slow evaporation, 
under low heat, yields the crystallized maple sugar product (1 L of syrup yields ca. 950 
g of sugar). In the seventeenth and eighteenth centuries, maple sugar was an important 
economic and political weapon in the fight to abolish slavery since cane sugar was 
associated with slave labor.1 Nowadays, it is highly regarded as a specialty natural 
sweetener and confectionery with the characteristic flavor and odor of pure maple syrup 
which is highly desired by many consumers. Moreover, similar to maple syrup, maple 
sugar is of significant cultural and economic importance to this region of the world. 
 Over recent years, a number of chemical compositional and biological studies 
have been conducted on maple-derived food products, namely, maple sap (functional 
beverage applications)2, maple syrup (food/sweetener applications),3-10 and maple 
syrup-derived extracts (nutraceutical/functional food applications).11-19 Notably, maple 
syrup and its derived extracts and pure compounds have been reported to show a wide 
range of biological effects in vitro and in vivo including antioxidant, anti-inflammatory, 
anticancer, antidiabetic, and neuroprotective properties.11-21 Therefore, given these 
promising data as well as the worldwide popularity and consumption of maple-derived 
food products, continued research to increase scientific knowledge of these natural 




Our laboratory has had an ongoing research program focused on the isolation, 
identification, and biological evaluation of compounds from maple-derived foods.2-5,9-
14,18-19  During these works, we reported on the isolation and structure elucidation (by 
NMR) of sixty-three compounds, primarily phenolics, as well as inulin, from these 
foods.2-5,10,13 Given that maple sugar has not been previously investigated, herein, our 
objectives were: 1) isolate and identify the phytochemicals in maple sugar using a 
combination of high resolution mass spectrometry (HRESIMS; by comparison to 
authentic standards previously isolated by our laboratory) and nuclear magnetic 
resonance (NMR; for those compounds for which we lacked authentic standards), and 
2) evaluate the isolates for their effects against inflammation in murine BV-2 
microglia in vitro and oxidative stress in Caenorhabditis elegans in vivo. This is the 





2.0 Materials and Methods 
 
2.1 General Experimental Procedures  
All nuclear magnetic resonance (1H and 13C NMR) were acquired on a Bruker 300 
MHz instrument using deuterated methanol (CD3OD) as solvent. High resolution 
electrospray ionization mass spectral (HRESIMS) data were acquired by direct 
infusion of the pure compounds on a Triple TOF 4600 (Applied Biosystems/MDS 
Sciex; Framingham, MA, USA) mass spectrometer equipped with a DuoSpray Ion 
Source. 
2.2 Chemicals 
ACS grade ethyl acetate was obtained from Pharmco-AAPER through Wilkem 
Scientific (Pawcatuck, RI, USA). The standards used for HRESIMS characterization 
were previously isolated and identified (by NMR and HRESIMS) by our laboratory.2-5 
MCI resin and LC-MS grades of acetonitrile and methanol were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). The C18 resin was purchased from Varian (Palo 
Alto, CA, USA). 
2.3 Maple sugar 
Maple sugar (25 Kg) was produced by the Federation of Maple Syrup Producers of 
Quebec (Longueil, Quebec, Canada) as previously reported by our laboratory.9 
Briefly, maple syrup (containing < 1 % inverted sugar to ensure crystallization) was 
slowly heated in baking pans (22-24°C) which were then cooled on a cold surface (ca. 
1 min per L) followed by immersion in cold water (for 2-5 min) to promote formation 
of the sugar crystals. As soon as crystals started to form, the mixture was stirred with a 




temperature dropped to below 32°C.  Once stirring was completed, the maple sugar 
crystals were sieved to desired particle size.  
2.4 Isolation of compounds 1-30 from maple sugar 
Maple sugar (1250 g) was dissolved in DI water (2.5 L) and extracted with ethyl 
acetate (3 x 2.5 L) at room temperature. The combined ethyl acetate extracts were 
concentrated under reduced pressure in vacuo to yield a dried maple sugar ethyl 
acetate extract (463 mg). The maple sugar ethyl acetate extract (463 mg) was initially 
purified by C18 resin medium pressure liquid column chromatography (glass column: 
350 mm in height and 50 mm in diameter) by eluting with a gradient solvent system of 
5%, 15%, 30%, 40%, 50%, 60%, 80%, and 100% of MeOH:H2O to yield nine 
fractions, A-I, respectively. Fractions A-F were further individually purified by MCI 
resin column chromatography (glass column: 305 mm in height and 25 mm in 
diameter) using gradient solvent systems of MeOH:H2O to yield compounds 1-30 as 
follows. Fraction A afforded compound 1 (0.1 mg); fraction B afforded compounds 2 
(0.5 mg), 3 (1.0 mg), 4 (0.1 mg), 5 (0.1 mg), 6 (0.1 mg), 7 (0.1 mg), 8 (0.7 mg), 9 (1.1 
mg), 10 (0.2 mg) and 11 (0.5 mg); fraction C afforded compounds 12 (1.0 mg), 13 (1.1 
mg), 14 (4.6 mg), 15 (1.2 mg), 16 (3.8 mg), 17 (0.9 mg), 18 (0.4 mg) and 19 (1.0 mg); 
fraction D afforded compounds 20 (1.1 mg), 21 (0.7 mg), 22 (0.9 mg) and 23 (0.9 
mg); fraction E afforded compounds 24 (0.8 mg), 25 (1.5 mg), 26 (0.5 mg), 27 (1.2 
mg) and 28 (1.2 mg); and fraction F afforded compounds 29 (0.2 mg) and 30 (0.2 mg). 
2.5 Identification of compounds 1-30 from maple sugar 
Our laboratory has previously isolated and identified (by NMR and HRESIMS) sixty-
three compounds from maple sap, maple syrup, and maple syrup-derived extracts.2-5,13 




HRESIMS (see Figure 1). Compounds 29 and 30, which were not previously isolated 
from these aforementioned maple-derived foods, were identified by NMR and 
HRESIMS (see below). 
Compound 29: (-) HRESIMS, m/z 809.3026 [M-H]-, calcd. for molecular formula 
C42H50O16; 1H-NMR (CD3OD, 300 MHz) δ 3.24 (m, H-8, 8'), 3.36 (m, H-9''b, 9'''b), 
3.61 (m, H- 9''a, 9'''a), 3.84 (s, OCH3-3'', 3''', 5'', 5'''), 3.85 (s, OCH3-3, 5, 3', 5'), 3.87 
(m, H-9b, 9'b), 3.91 (m, H-8''b, 8'''b), 4.30 (m, H-9a, 9'a), 4.78 (m, H-7, 7'), 4.90 (m, 
H-7'', 7'''), 6.70 (s, H-2, 6, 2', 6'), 6.74 (brs, H-6'', 6'''), 6.79 (brs, H-5'', 5'''), 6.99 (brs, 
H-2'', 2'''); 13C-NMR (CD3OD, 75 MHz) δ 55.7 (C-8, 8'), 56.3 (OCH3-3'', 3''', 5'', 5'''), 
56.7 (OCH3-3, 3', 5, 5'), 61.7 (C-9'', 9'''), 73.1 (C-9, 9'), 74.1 (C-7'', 7'''), 87.2 (C-7, 7'), 
104.3 (C-2, 6, 2', 6'), 111.4 (C-2'', 2'''), 115.6 (C-5'', 5'''), 120.7 (C-6'', 6'''), 133.8 (C-1'', 
1'''), 136.1 (C-4, 4'), 138.9 (C-1, 1'), 146.9 (C-4'', 4'''), 148.6 (C-3'', 3'''), 154.5 (C-3, 5), 
154.5 (C-3', 5').22 
Compound 30: (-) HRESIMS, m/z 809.3053 [M-H]-, calcd. for molecular formula 
C42H50O16; 1H-NMR (CD3OD, 400 MHz) δ 3.24 (m, H-8, 8'), 3.34 (m, H-9'''b), 3.45 
(m, H-9''b), 3.68 (m, H-9'''a), 3.83 (s, OCH3-3''', 5'''), 3.84 (s, OCH3-3'', 5''), 3.85 (m, 
H-9''a), 3.88 (s, OCH3-3, 5), 3.89 (s, OCH3-3', 5'), 3.93 (m, H-9b, 9’b), 3.96 (m, H-
8'''), 4.11 (m, H-8''), 4.29 (m, H-9a, 9'a), 4.78 (m, H-7, 7'), 4.99 (brs, H-7'', 7'''), 6.71 
(brs, H-2, 6, 2', 6'), 6.74 (brs, H-5'', 5'''), 6.87 (brs, H-6'', 6'''), 6.99 (brs, H-2'', 2'''). 13C-
NMR (CD3OD, 75 MHz) δ 55.7 (C-8, 8'), 56.3 (OCH3-3'', 3''', 5'', 5'''), 56.7 (OCH3-3, 
3', 5, 5'), 61.7 (C-9''), 61.8 (C-9'''), 73.0 (C-9, 9'), 74.0 (C-7''), 74.3 (C-7'''), 87.2 (C-7, 
7'), 87.3 (C-8''), 88.7 (8'''), 104.2 (C- 2', 6'), 104.3 (C- 2, 6), 111.4 (C-2''), 111.6 (C-




1'''), 136.1 (C-4), 136.7 (C-4'), 138.9 (C-1), 139.1 (C-1'), 146.8 (C-4''), 147.1 (C-4'''), 
148.7 (C-3''), 148.7 (C-3'''), 154.3 (C-3', 5'), 154.5 (C-3, 5).22 
2.5 Analytical High Performance Liquid Chromatography with Diode Array 
Detection (HPLC-DAD) 
HPLC-DAD analyses were performed on a Hitachi Elite LaChrom system 
(Pleasanton, CA, USA) consisting of a L2130 pump, a L-2200 autosampler, and a L-
2455 Diode Array Detector, operated by EZChrom Elite software. Chromatographic 
separation was performed on a Waters Sunfire C18 column (250 mm × 4.6 mm i.d., 5 
μm, Waters, Massachusetts, U.S.A.) with a Waters Sunfire C18 VanGuard Pre-
Column (20 mm × 4.6 mm i.d., 5 μm, Waters, Massachusetts, U.S.A.). The mobile 
phase consisted of 0.1% (v/v) formic acid/ water (A) and methanol (B), with a 
gradient elution at room temperature as follow: 0-5 min, 5% B; 5-165 min, from 5% to 
53% B; 165-212 min, from 53% to 100% B; 212-224 min, 100% B. The flow rate was 
at 1.0 mL/min, the injection volumes were 20 μL, and the detection wavelength was 
280 nm. 
2.6 Ultra-Fast Liquid Chromatography Mass Spectrometry (UFLC-ESI-TOF-
MS) 
UFLC-ESI-TOF-MS analyses were performed on a SHIMADZU Prominence UFLC 
system (Marlborough, MA, USA) consisting of two LC-20AD pumps, a DGU-20A 
degassing unit, SIL-20AC auto sampler, CTO-20AC column oven and CBM-20A 
communication bus module. Chromatographic separation was performed on a Waters 
XBridge® BEH C18 column (100 mm × 2.1 mm i.d., 2.5 μm. Milford, MA, USA). The 
mobile phase consisted of 0.1% (v/v) formic acid:acetonitrile (solvent A) and 0.1% 




27-97% A from 96-97 min, and 97% A from 97-110 min. The column temperature 
was 40 °C, flow rate was 0.2 mL/min, and injection volume was 4 μL. Mass 
spectrometry was performed using a Triple TOF 4600 system from Applied 
Biosystems/MDS Sciex (Framingham, MA, USA) coupled with an electrospray 
ionization (ESI) interface. Nitrogen was used in all cases. In this study, the parameters 
were optimized as follows: ESI voltage, -4500 V; nebulizer gas, 40; auxiliary gas, 60; 
curtain gas, 30; turbo gas temperature, 600°C; declustering potential, -70V. Instrument 
calibration was carried out according to the manufacturer’s instructions. The mass 
range was set from m/z 100 to 1000 and the mass range for product ion scan was m/z 
100-1000. The data were acquired and processed using Analyst TF 1.7 Software.  
2.7 Sample preparation for HPLC-DAD and UFLC-ESI-TOF-MS analyses 
The maple sugar ethyl acetate extract (20 mg) was dissolved in 4 mL 60% aqueous 
methanol (LC-MS grade). The solution was stored at 4 °C and filtered (0.22 micron 
filter) before analyses. 
2.8 Isolates for bioassays 
Based on availability of the pure compounds isolated from maple sugar (obtained in 
quantities > 0.5 mg), we evaluated twenty-one of the thirty isolates as follows:  2, 3, 8, 
9, 11-17, 19- 28.  
2.9 Cell culture conditions 
Murine BV-2 microglia were a kind gift from Dr. Grace Sun (University of Missouri, 
Columbia, MO, USA). The cells were cultured in DMEM (Life Technologies, Grand 
Island, NY, USA) supplemented with 10% Fetal Bovine Serum (Gibco, Grand Island, 
NY, USA) and penicillin/ streptomycin antibiotics (1%) (Gibco, Grand Island, NY, 




approximately 37°C under 5% CO2. Prior to seeding, cells were examined for their 
viability and counted using trypan blue staining and a hemocytometer.  
2.10 Anti-inflammatory assay (by measuring nitric oxide release with the Griess 
reagent) 
The murine BV-2 microglia cells were cultured as previously described by our 
laboratory.18 In brief, microglia were seeded into 24-well plates at a density of 
approximately 100,000 cells/mL. Cells were serum starved after following a 24 h 
incubation period to ensure adherence. Cells were then exposed to either pure 
compounds (at 10 μM), the positive control, resveratrol (RESV; at 10 μM), or vehicle 
control for 1 hr. Lipopolysaccharide (LPS; at a concentration of 1 μg/mL) was then 
added directly to the cells and allowed to incubate for 23 hours. Following this 
incubation period, the total nitric oxide released into cell culture media was quantified 
using the Greiss Reagent System (Promega, Madison, WI, USA).  
2.11 Caenorhabditis elegans maintenance 
Wild-type (N2) Caenorhabditis elegans were obtained from the Caenorhabditis 
Genetics Center (CGC) at the University of Minnesota (Minneapolis, MN, USA). 
Worm cultures were maintained on Nematode Growth Medium (NGM) (1.7% Agar, 
0.3% NaCl, 0.25% peptone, 1 mM CaCl2, 1 mM MgSO4, 5 mg/L cholesterol in 
ethanol, and 2.5 mM KPO4) in petri dishes at 20°C with UV-killed OP50 Escherichia 
coli as a food source. Age synchronous cultures were obtained by the standard 
hypochlorite method as previously reported by our laboratory.18 For sample treatment, 
C. elegans were washed from their plates with liquid nematode growth medium (0.3% 




2.5 mM KPO4) and transferred to culture flasks containing UV-killed OP50 E. coli as 
a food source.  
2.12 Caenorhabditis elegans oxidative stress resistance assay 
To determine if oxidative stress resistance is improved in C. elegans, a method to 
induce oxidative stress was adapted as previously reported with minor modifications.23 
Briefly, age synchronous culture of N2 (L2) worms in liquid NGM were transferred 
into the wells of a 96-well plate. To each individual well, compounds were added to 
achieve a final concentration of 10 µM. A solvent control well was made by adding 
DMSO/water solution to achieve a final DMSO concentration of 0.01%. The cultures 
were incubated in the dark for 24 h. After incubation with the compounds, the cultures 
were exposed to 400 µM of 5-hydroxy-1,4-napthoquinine (also known as juglone). 
Immediately after the addition of juglone, a baseline count was taken with a dissecting 





3.0 Results and Discussion  
 
3.1 Isolation and identification of compounds in maple sugar 
Our laboratory has conducted extensive studies on maple sap and maple syrup which 
has led to the isolation and identification (by NMR) of sixty-three compounds, 
predominantly phenolics, belonging to the lignan sub-class.2-5,13 Given our group’s 
access to these authentic maple standards (many of which are not commercially 
available), we initially compared the HPLC-DAD profiles of the ethyl acetate extracts 
of maple syrup and maple sugar. As expected, there were marked similarities in the 
chromatograms of maple syrup and maple sugar suggesting that the phenolic 
compounds present in maple syrup were preserved in the slow heating evaporation 
process required for its transformation to maple sugar.  This was in support of our 
previous findings where we reported that the natural phenolic compounds present in 
maple sap are also preserved in the intensive heating/boiling process required in its 
transformation to maple syrup.2 Thus, while flavor/odor compounds are created during 
the cooking/boiling process of transforming maple sap to maple syrup, it was apparent 
that the majority of the phenolic compounds originally present in the xylem sap of the 
maple tree persist in maple syrup and maple sugar.  
In our previous research projects on maple sap and maple syrup, 2-5,13 we obtained 
the majority of the isolates in limited quantities which have since been exhausted 
thereby hampering their evaluation in bioassays. Therefore, although we did not seek to 
‘comprehensively re-isolate’ all of the compounds in maple sugar, we were able to 
isolate (using chromatography) and identify (using HRESIMS and NMR) thirty (1-30) 
of its constituents from a maple sugar ethyl acetate extract. Figure 1 shows the total ion 




identities of compounds 1-30 shown in Table 1 and their structures shown in Figure 2. 
It should be noted that compounds 1-28 were identified by HRESIMS (by comparison 
with authentic standards previously isolated by our laboratory2-5,13) while compounds 29 
and 30 (for which we lacked authentic standards) were identified by NMR (further 
described below).  
Thus, based on retention times (tR) and accurate m/z of pseudo molecular ions (by 
comparison to authentic standards), compounds 1-28 were identified as 2,3-dihydroxy-
1-(3,4-dihydroxyphenyl)-1-propanone (1), C-veratroylglycol (2), 2,3-dihydroxy-1-(4-
hydroxy-3,5-dimethoxyphenyl)-1-propanone (3), (erythro,erythro)-1-[4-(2-hydroxy-2-
(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethoxy)-3-methoxyphenyl]-1,2,3-
propanetriol (4), 1,2-diguaiacyl-1,3-propanediol (5), (erythro,erythro)-1-[4-[2-
hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethoxy]-3,5-
dimethoxyphenyl]-1,2,3-propanetriol (6), epicatechin (7), (threo,erythro)-1-[4-[2-
hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethoxy]-3,5-
dimethoxyphenyl]-1,2,3-propanetriol (8), 3-hydroxy-1-(4-hydroxy-3,5-
dimethoxyphenyl)propan-1-one (9), coumaric acid (10), leptolepisol D (11), 
guaiacylglycerol-β-O-4'-coniferyl alcohol (12), lyoniresinol (13), threo-
guaiacylglycerol-β-O-4'-dihydroconiferyl alcohol (14), isolariciresinol (15), erythro-














3-methoxyphenyl)-1,3-propanediol (27) and buddlenol E (28). Since we lacked 
authentic standards for compounds 29 and 30, they were identified as two di-lignans by 
NMR data (provided in the Methods section) as (7R,7'R,7''S,7'''S,8S,8'S,8''S,8'''S)-4'',4'''-
dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9';7', 9-diepoxy-4,8'';4',8'''-bisoxy-8,8'-
dineolignan-7'',7''',9'',9'''-tetraol (29) and (7R,7'R,7''R,7'''S,8S,8'S,8''S,8'''S)-4'',4'''-
dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9';7', 9-diepoxy-4,8'';4',8'''-bisoxy-8,8'-
dineolignan-7'',7''',9'',9'''-tetraol (30). The NMR data of these di-lignans were in 
agreement with published values.22 Whilst this is the first report of these di-lignans in a 
maple-derived food product, given that these are naturally occurring plant secondary 
metabolites, it is highly likely that they are also present in maple sap and maple syrup 
but were not isolated/obtained in our previous studies. 2-5,13 As shown in the HPLC-DAD 
chromatograms of maple syrup and maple sugar, there are many minor peaks present in 
these foods and obtaining all of these compounds is not possible due to a variety of 
reasons including complicated matrix with multiple overlapping peaks, low yields of 
isolates, etc.  Nevertheless, overall, similar to our previous observations for maple sap 
and maple syrup, 2-5,13 the majority of the phenolic compounds found in maple sugar are 
also lignans.  





Our group has previously utilized a murine BV-2 microglia cell model to evaluate the 
anti-inflammatory effects of a phenolic-enriched maple syrup extract.18 However, as 
previously mentioned, because of limited sample quantities available, the pure maple 
compounds were not assayed in that study. Therefore, herein, the BV-2 murine 
microglia were pre-treated with twenty-one of the maple sugar isolates (obtained > 0.5 
mg), namely, compounds 2, 3, 8, 9, 11-17, and 19- 28 (at 10 µM) for one hour (Figure 
3A). Resveratrol (RESV; at 10 and 20 μM) was used as a positive control since this 
natural polyphenol is well-known for its anti-inflammatory properties.18 Immediately 
following pre-treatment with the compounds, lipopolysaccharide (LPS) was added to 
stimulate the production of nitric oxide (NO). Total NO concentrations found in cell 
culture media of LPS-treated cells were approximately 33.85 μM ± 0.23 as compared to 
vehicle treated cells which released approximately 0.69 μM ± 0.04 of NO. RESV 
produced significantly lower NO media levels by approximately 16.36% (28.31 μM 
±0.33) and 33.76% (22.42 μM ± 0.05) at 10 and 20 μM respectively (Figure 3A). 
Among the isolates, compounds 3, 8, 9, 17, and 24 significantly decreased NO levels as 
follows 9.89% (30.5 μM ± 0.14), 18.52% (27.58 μM ±0.72), 4.99% (32.16 μM ± 0.23), 
4.96% (32.17 μM ± 0.41) and 9.57% (30.61μM ± 0.84), respectively (Figure 3B). Based 
on this data, it is not possible to make any structure activity related (SAR) inferences 
given the structural diversity of the compounds.  
3.3 Evaluation of effects of maple sugar isolates on oxidative stress in 
Caenorhabditis elegans in vivo 
Natural products, including resveratrol, have been shown to improve oxidative stress 
resistance and life span in Caenorhabditis elegans after exposure to the pro-oxidant, 




generated for the twenty-one maple sugar isolates and their Mantel-Haenszel Ratio 
(MHR) are listed in Table 3. Nine of the twenty-one compounds extended lifespan of 
C. elegans in a high-oxidative stress environment by a statistically significant margin 
(P< 0.01), namely, 16, 17, 20-24, 26, and 28 indicating that these compounds were 
mitigating the toxicity of juglone. Similar to the data accumulated from the in vitro BV-
2 cell assay, it is not possible to make any SAR inferences given the structural diversity 
of the compounds.  
In summary, this is the first study to isolate, identify, and biologically evaluate the 
phytochemicals present in the traditional North American confectionery, maple sugar.  
Similar to other maple-derived food products, maple sugar contains a variety of 
phenolic compounds among which the lignan sub-class predominate. The protective 
effects of the maple sugar isolates against inflammation (in BV-2 microglia in vitro) 
and oxidative stress (in C. elegans in vivo) is in agreement with a vast body of 
literature supporting similar effects for phenolic compounds found in plant foods. 
Whether these biological effects are translatable in vivo would require animal studies 




4.0 Acknowledgments  
 
The authors gratefully acknowledge the Federation of Quebec Maple Syrup Producers 
(Longueuil, Quebec, Canada) and Agriculture and Agri-Food Canada for funding of 
this research project. Research reported in this publication was made possible by the 
use of equipment and services available through the RI-INBRE Centralized Research 
Core Facility which is supported by the Institutional Development Award (IDeA) 
Network for Biomedical Research Excellence from the National Institute of General 







(1) Davis, K.C. A sweet assault on slavery. http://www.huffingtonpost.com/kenneth-c-
davis/maple-sugar-slavery_b_833972.html (Accessed Febrary 19, 2017) 
 
(2) Yuan, T.; Li, L.; Zhang, Y.; Seeram, N. P. Pasteurized and sterilized maple sap as 
functional beverages: chemical composition and antioxidant activities. J. Funct. Foods 
2013, 5, 1582-1590. 
 
(3) Li, L.; Seeram, N. P. Maple syrup phytochemicals include lignans, coumarins, a 
stilbene, and other previously unreported antioxidant phenolic compounds. J. Agric. 
Food Chem. 2010, 58, 11673-11679. 
 
(4) Li, L.; Seeram, N. P. Further investigation into maple syrup yields 3 new lignans, a 
new phenylpropanoid, and 26 other phytochemicals. J. Agric. Food Chem. 2011, 59, 
7708-7716. 
 
(5) Li, L.; Seeram, N. P. Quebecol, a novel phenolic compound isolated from Canadian 
maple syrup. J. Funct. Foods 2011, 3, 125-128. 
 
(6) Watanabe, Y.; Kamei, A.; Shinozaki, F.; Ishijima, T.; Iida, K.; Nakai, Y.; Arai, S.; 
Abe, K. Ingested maple syrup evokes a possible liver-protecting effect-physiologic 
and genomic investigations with rats. Biosci., Biotechnol., Biochem. 2011, 75, 2408-
2410. 
 
(7) Nagai, N.; Ito, Y.; Taga, A. Comparison of the enhancement of plasma glucose 
levels in type 2 diabetes Otsuka Long-Evans Tokushima fatty rats by oral 
administration of sucrose or maple syrup. J. Oleo Sci. 2013, 62, 737-743. 
 
(8) Nagai, N.; Yamamoto, T.; Tanabe, W.; Ito, Y.; Kurabuchi, S.; Mitamura, K.; Taga, 
A. Changes in plasma glucose in Otsuka Long- Evans Tokushima fatty rats after oral 
administration of maple syrup. J. Oleo Sci. 2015, 64, 331-335. 
 
(9) Liu, Y.; Ma, H.; Seeram, N. P. Development and UFLC-MS/MS characterization of 
a product-specific standard for phenolic quantification of maple-derived foods. . J. 
Agric. Food Chem. 2016, 64, 3311-3317. 
 
(10) Sun, J; Ma, H.; Seeram, N. P.; Rowley, D. C. Detection of inulin, a prebiotic 
polysaccharide, in maple syrup. J. Agric. Food Chem. 2016, 64, 7142-7147. 
 
(11) Apostolidis, E.; Li, L.; Lee, C.; Seeram, N. P. In vitro evaluation of phenolic-
enriched maple syrup extracts for inhibition of carbohydrate hydrolyzing enzymes 
relevant to type 2 diabetes management. J. Funct. Foods 2011, 3, 100-106. 
 
(12) Gonzaĺez-Sarrías,A.; Li,L.; Seeram,N.P. Anticancer effects of maple syrup 
phenolics and extracts on proliferation, apoptosis, and cell cycle arrest of human colon 





(13) Zhang, Y.; Yuan, T.; Li, L.; Nahar, P.; Slitt, A.; Seeram, N. P. Chemical 
compositional, biological, and safety studies of a novel maple syrup derived extract 
for nutraceutical applications. J. Agric. Food Chem. 2014, 62, 6687-6698. 
 
(14) Nahar, P. P.; Driscoll, M. V.; Li, L.; Slitt, A. L.; Seeram, N. P. Phenolic mediated 
anti-inflammatory properties of a maple syrup extract in RAW 264.7 murine 
macrophages. J. Funct. Foods 2014, 6, 126-136. 
 
(15) Maisuria, V. B.; Hosseinidoust, Z.; Tufenkji, N. Polyphenolic extract from maple 
syrup potentiates antibiotic susceptibility and reduces biofilm formation of pathogenic 
bacteria. Appl. Environ. Microbiol. 2015, 81, 3782-3792. 
 
(16) Kamei, A.; Watanabe, Y.; Shinozaki, F.; Yasuoka, A.; Kondo, T.; Ishijima, T.; 
Toyoda, T.; Arai, S.; Abe, K. Administration of a maple syrup extract to mitigate their 
hepatic inflammation induced by a high- fat diet: a transcriptome analysis. Biosci., 
Biotechnol., Biochem. 2015, 79, 1893-1897. 
 
(17) Hawco, C. L.; Wang, Y.; Taylor, M.; Weaver, D. F. A maple syrup extract prevents 
β-amyloid aggregation. Can. J. Neurol. Sci. 2016, 43, 198-201. 
 
(18) Ma, H.; DaSilva, N. A.; Liu, W.; Nahar, P. P.; Wei, Z.; Liu, Y.; Pham, P. T.; Crews, 
R.; Vattem, D. A.; Slitt, A. L.; Shaikh, Z. A.; Seeram, N. P. Effects of a standardized 
phenolic-enriched maple syrup extract on β-amyloid aggregation, neuroinflammation 
in microglial and neuronal cells, and β-amyloid induced neurotoxicity in 
Caenorhabditis elegans. Neurochem. Res. 2016, 41, 2836-2847. 
 
(19) Liu, W.; Wei, Z.; Ma, H.; Cai, A.; Liu, Y.; Sun, J.; DaSilva, N.; Johnson, S.; 
Kirschenbaum, L. J.; Cho, B.; Dain, J.; Rowley, D.; Shaikh, Z.; Seeram, N. P. Anti-
glycation and anti-oxidative effects of a phenolic-enriched maple syrup extract and its 
protective effects on normal human colon cells. Food Funct. 2017, in press, DOI: 
10.1039/c6fo01360k 
 
(20) Cardinal, S.; Azelmat, J.; Grenier, D.; Voyer, N. Anti-inflammatory properties of 
quebecol and its derivatives. Bioorg. Med. Chem. Lett. 2016, 26, 440-444. 
 
(21) Cardinala, S.; Paquet, P.; Azelmatb, J.; Boucharda, C.; Grenier, D.; Voyer, N. 
Synthesis and anti-inflammatory activity of isoquebecol. Bioorg. Med. Chem. 2017, in 
press, DOI: 10.1016/j.bmc.2017.01.050 
 
(22) Zhu, J. X.; Ren, J.; Qin, J. J.; Cheng, X. R.; Zeng, Q.; Zhang, F.; Yan, S. K.; Jin, 
H. Z.; Zhang, W. D. Phenylpropanoids and lignanoids from Euonymus acanthocarpus. 
Arch. Pharm. Res. 2012, 35, 1739-1747. 
 
(23) Chen, W.; Rezaizadehnajafi, L.; Wink, M. Influence of resveratrol on oxidative 
stress resistance and life span in Caenorhabditis elegans. J. Pharm. Pharmacol. 2013, 
65, 682-688. 
 




thioallyl compounds increase oxidative stress resistance and lifespan in 
























Figure 3.  Anti-inflammatory effects of maple sugar isolates assayed by 
measuring nitric oxide release by murine BV-2 microglia after exposure to 
lipopolysaccharide (LPS). Fig. 3A BV-2 microglia were pretreated with twenty-one 
isolates (10 μM), positive control, resveratrol (RESV; 10 and 20 μM) or vehicle 
control (DMSO) for one hour prior to lipopolysaccharide (LPS) stimulation at 1 
μg/mL for 23 hours. The total NO concentrations were assayed using the Greiss 
Assay. Fig. 3B. At 10 μM, compounds 3, 8, 9, 17, and 24 and RESV significantly 
decreased NO release as compared to the cells treated with LPS-alone. Statistical 
significance as determined by student’s t-test was determined as follows p < 0.05 * ; 








Table 1. UFLC-ESI-TOF-MS data for compounds identified in maple sugar ethyl 














1 2,3-dihydroxy-1-(3,4-dihydroxyphenyl)-1-propanone 4.71 197.0462 (197.0455) 3.3132 C9H10O5 
2 
C-veratroylglycol 































































































































































































Table 2. Effects of maple sugar isolates on oxidative stress induced by exposure to 
juglone in Caenorhabditis elegans Age synchronous C. elegans were treated with the 
maple sugar isolates (10 µM) for 24 h after which the pro-oxidant, juglone was added 
(400 µM). Living worms were counted every hour for six hours. Kaplan-Meier 
survival curves were constructed using GraphPad Prism 7. The Mantel-Haenszel ratios 
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Medicinal plants are promising candidates for Alzheimer’s disease (AD) research but 
there is lack of systematic algorithms and procedures to guide their selection and 
evaluation.  Herein, we developed an AD Neuroprotective Potential Algorithm (NPA) 
by evaluating twenty-three standardized and chemically characterized Ayurvedic 
medicinal plant extracts in a panel of bioassays targeting oxidative stress, carbonyl 
stress, protein glycation, amyloid beta (Aβ) fibrillation, acetylcholinesterase (AChE) 
inhibition, and neuroinflammation.  The twenty-three herbal extracts were initially 
evaluated for: 1) total polyphenol content (Folin-Ciocalteu assay), 2) free radical 
scavenging capacity (DPPH assay), 3) ferric reducing antioxidant power (FRAP assay), 
4) reactive carbonyl species scavenging capacity (methylglyoxal trapping assay), 5) 
anti-glycative effects (BSA-fructose, and BSA-methylglyoxal assays) and, 6) anti-Aβ 
fibrillation effects (thioflavin-T assay). Based on assigned index scores from the initial 
screening, twelve extracts with a cumulative NPA score ≥ 40 were selected for further 
evaluation for their: 1) inhibitory effects on AChE activity, 2) in vitro anti-inflammatory 
effects on murine BV-2 microglial cells (Griess assay measuring levels of 
lipopolysaccharide-induced nitric oxide species), and 3) in vivo neuroprotective effects 
on Caenorhabditis elegans post induction of Aβ1-42 induced neurotoxicity and paralysis. 
Among these, four extracts had a cumulative NPA score ≥ 60 including Phyllanthus 
emblica (amla; Indian gooseberry), Mucuna pruriens (velvet bean), Punica granatum 
(pomegranate) and Curcuma longa (turmeric; curcumin). These extracts also showed 
protective effects on H2O2 induced cytotoxicity in differentiated cholinergic human 
neuronal SH-SY5Y and murine BV-2 microglial cells and reduced tau protein levels in 




effects of several of these Ayurvedic medicinal plant extracts, some remain unexplored 
for their anti-AD potential.  Therefore, the NPA may be utilized, in part, as a strategy to 
help guide the selection of promising medicinal plant candidates for future AD-based 




1.0 Introduction  
Alzheimer’s disease (AD) is a common neurodegenerative disorder characterized by the 
progression of cognitive decline leading to severe dementia (Buckner et al., 2005).  The 
accumulation of senile plaques and neurofibrillary tangles in cerebral cortex and 
hippocampus are two major pathological hallmarks of AD (Ittner and Götz, 2011). 
However, due to the complexity of the disease, the precise factors which trigger the 
development of AD remains unknown (Alzheimer’s Association, 2015). Moreover, 
given the unclear etiology of AD, current therapeutic approaches focus mainly on 
symptom management but no treatment is available to alter or reverse the course of the 
disease (Alzheimer’s Association, 2015; Citron, 2010). Although the pathogenesis of 
AD is still under investigation, increasing evidence suggest that AD is a multifactorial 
disease which develops as a result of several risk contributors instead of a single cause 
alone (Norton et al., 2014; Reitz and Mayeux, 2014).  
Oxidative stress and the production of reactive oxygen species (ROS) have been 
implicated in the pathogenesis of AD and are believed to be leading causative factors 
for neuronal cell dysfunction and cell death (Lin and Beal, 2006; Smith et al., 2000). It 
has been demonstrated that the products of protein oxidation and lipid peroxidation are 
elevated in AD patients (Christen, 2000). In addition, in the AD brain, the activities of 
antioxidant enzymes are altered, accompanied with a decline in the expression of these 
antioxidant enzymes (Christen, 2000; Smith et al., 2000). Given the established links 
between oxidative stress and AD, antioxidants, including those from natural products, 
are extensively studied for their neuroprotective abilities and constitute dietary 
intervention strategies for AD prevention and treatment (Alzheimer’s Association, 




Apart from oxidative stress, carbonyl stress and the formation of advanced glycation 
end-products (AGEs) resulting from protein glycation are also believed to be vital 
contributors to AD (Srikanth et al., 2011; Vicente Miranda and Outeiro, 2010). 
Glycation is one type of post-translational modification of proteins, resulting in the 
formation of AGEs both intracellularly and extracellularly. Glycation and AGEs 
formation are associated with AD due to several reasons. First, AGEs bind to the 
transmembrane receptor, RAGE (receptor for AGEs), upregulate RAGE expression, 
and activate RAGE-mediated neuronal dysfunction and neuron damages (Srikanth et 
al., 2011). Second, RAGE mediates the transportation of beta amyloid (Aβ) across the 
blood brain barrier (BBB) (Donahue et al., 2006). Therefore, the activation of RAGE 
by AGE can cause Aβ accumulation in the brain. Third, during the course of glycation 
and AGE formation, ROS and reactive carbonyl species (RCS) are generated as by-
products which, in turn, promote AGE formation and cause neurotoxicity (Ahmed et 
al., 2005; Münch et al., 2012; Picklo et al., 2002). Consequently, all of the factors 
involved in this positive feedback loop including AGEs, RCS, and ROS are considered 
to be promising targets for AD prevention and treatment.  
Another common target for AD therapy is the Aβ peptide which consists of 40 to 42 
amino acids and is generated from the cleavage of the Aβ precursor protein. Aβ is the 
major component of senile plaques and neurofibrillary tangles, two pathological 
hallmarks of AD (Buckner et al., 2005; Palop and Mucke, 2010). In AD patients, 
elevated Aβ levels were observed in both cerebrospinal fluid and blood (Mawuenyega 
et al., 2010). In addition, certain forms of Aβ, including fibrillated Aβ and glycated Aβ 
(Aβ-AGEs), have been shown to be neurotoxic (Butterfield, 2002; Koo et al., 1999; Li 




stress and neuroinflammation (Butterfield, 2002; Koo et al., 1999). Aβ-AGEs can 
induce intracellular oxidative stress and inflammation by activating RAGE and 
upregulating RAGE expression in neuronal cells (Li et al., 2013). Therefore, 
considerable research efforts have been directed to finding inhibitors which may prevent 
or reverse the formation of Aβ fibrils and Aβ-AGEs. For example, aminoguanidine 
(AG), a synthetic glycation inhibitor, can reduce glycated Aβ formation, attenuate 
RAGE upregulation, and restore the cognitive deficit in AD animal models (Li et al., 
2013). However, AG failed in human clinical trials due to severe side effects 
(Thornalley, 2003) leading to the search for non-toxic alternatives including medicinal 
plants and their derived natural products and botanical extracts (Solanki et al., 2016; 
Venigalla et al., 2016). 
In addition to oxidative stress, glycation, and Aβ formation, neuroinflammation is 
another pivotal factor implicated in the development of neurodegenerative diseases with 
increased inflammation observed in AD (Eikelenboom et al., 2002). In addition, 
inflammatory stress leads to the activation of microglia cells, the immune cells in the 
central nervous system, which release nitric oxide species (NOS) including nitrates and 
nitrites. These NOS are neurotoxic and cause massive neuronal death further 
exacerbating neurodegenerative diseases (Eikelenboom et al., 2002; Eikelenboom et al., 
2006). 
For centuries, traditional systems of medicines such as Ayurveda [from India, a country 
which has one of the lowest incidences of AD worldwide (Chandra et al., 2001; Vas et 
al., 2001)] and traditional Chinese medicine (TCM) (Steele et al., 2013), have used 
medicinal plants to treat several ailments including neurodegenerative diseases. While 




medicinal plants, there is a lack of systematic procedures and algorithms to help guide 
the selection and evaluation of the most promising candidates for further AD-based 
research using animal models. This is urgently needed given the large variety of 
medicinal plant species (and combinations thereof) used worldwide in the traditional 
systems of medicines of various cultures. Furthermore, although medicinal plants are 
consumed as foods, herbs, spices, beverages, and botanical extracts, their underlying 
mechanisms of neuroprotective effects remain unclear. Therefore, given all of the 
aforementioned factors, herein, we utilized a panel of bioassays including total 
polyphenol contents, antioxidant capacities, anti-glycation effects, carbonyl scavenging 
abilities, anti-Aβ fibrillation, acetylcholinesterase (AChE) inhibition, and anti-
neuroinflammatory activities to develop a Neuroprotective Potential Algorithm (NPA) 
to aid in the evaluation and selection of promising medicinal plant candidates for future 
AD based research using pre-clinical animal models (see Figure 1). We selected 
twenty-three commercially available and chemically characterized medicinal plant 
extracts (see Table 1), commonly consumed as foods (in India, and elsewhere), and 





2.0 Materials and Methods  
2.1. Chemicals 
The herbal extracts are botanically authenticated and chemically standardized GRAS 
(generally regarded as safe) extracts which are commercially available for human 
consumption and sourced from a single reputable natural products supplier, namely, 
Verdure Sciences (Noblesville, IN, USA), to ensure access to validated and consistent 
samples. The Latin binomial and common names, as well as the traditional uses, of the 
twenty-three medicinal plant species are provided in Table 1. Each extract was 
dissolved in DMSO (20.0 mg/mL) and diluted to test concentrations (10-2000 μg/mL) 
with 0.1 M phosphate buffer (pH=7.2).  The following chemicals were purchased from 
Sigma-Aldrich Chemical Co. (St. Louis, MO, USA): butylated hydroxytoluene (BHT), 
bovine serum albumin (BSA), methylglyoxal (MGO), aminoguanidine hydrochloride 
(AG), gallic acid, resveratrol (RESV), galanthamine, 1,2-phenylenediamine (PD), 2,3-
dimethylquinoxaline (DQ), 2,4,6-tripyridyl-s-triazine, iron (III) chloride hexahydrate, 
L-ascorbic acid, HPLC-grade methanol and trifluoroacetic acid (TFA), thioflavin T 
agent (ThT), Tris-HCl buffer (pH 8.0), acetylcholinesterase (AChE; from electric eel), 
5,5′-dithiobis(2-nitrobenzoic acid) (DTNB), and acetylthiocholine iodide (ATCI).  
Human beta amyloid 1-42 (Aβ1-42) peptide (Catalog #: AS-2027) was purchased from 
Anaspec (San Jose, CA, USA). 
2.2. Antioxidant assays 
2.2.1. Free radical scavenging activity (DPPH assay) 
The extracts were evaluated for their free radical scavenging capacity by the 2,2-
diphenyl-1-picrylhydrazyl (DPPH) assay as previously reported by our laboratory (Ma 




mixed with 100 μL of a 0.2 mM DPPH solution in a 96-well plate. After incubation at 
room temperature for 30 min, sample absorbance was read (at 517 nm) using a 
microplate reader (SpectraMax M2, Molecular Devices Corp., Sunnyvale, CA, USA).  
2.2.2. Ferric reducing antioxidant power (FRAP assay) 
The ferric reducing antioxidant power (FRAP) of the extracts were measured following 
published methods (Maksimović et al., 2005; Tsai et al., 2002). The FRAP reagent 
contained 100 mL acetate buffer (3 mM, pH 3.6), 10 mL 2,4,6-tripyridyl-s-triazine (10 
mM) in 40 mM hydrochloric acid, and 10 mL FeCl3·6H2O (20 mM). Briefly, 1.5 mL 
of freshly prepared FRAP reagent was mixed with 50 µL of each extract (final 
concentration of 100 µg/mL) and the absorbance was measured at 593 nm after 5 
minutes using an UltroSpec 2100 instrument (Biochrom Ltd, Cambridge, UK).  L-
ascorbic acid (0.1 - 3 mM) was used as the positive control and to generate a calibration 
curve.  The FRAP capacity of each extract was expressed as ascorbic acid equivalents 
(AAE)/mg where AAE is defined as follows: the reducing power of 1 mg dry plant 
material is equivalent to the reducing power of 1 nM of L-ascorbic acid (Maksimović 
et al., 2005). All data were the average of three individual experiments. 
2.3. Total polyphenol content  
The extracts were quantified for total phenolic content using the Folin–Ciocalteu 
method and expressed as gallic acid equivalents (GAEs) as previously reported by our 
laboratory (Jean-Gilles et al., 2012). Briefly, each sample (5 mg) was dissolved in 500 
μL of 50% aqueous methanol, and 100 μL of each sample was incubated with 50 μL of 
the Folin–Ciocalteu reagent for 5 min at room temperature. Then 150 μL of a 20% 
sodium carbonate (Na2CO3) solution and 250 μL of distilled water were added to each 




incubated for 30 min at 40 °C and then immediately cooled to room temperature. The 
standard (i.e. gallic acid) was prepared in parallel with the samples. Each sample was 
centrifuged and 200 μL of supernatant was added to a 96-well plate and absorbance read 
at 756 nm on a Spectramax plate reader (SpectraMax M2, Molecular Devices Corp., 
Sunnyvale, CA, USA). 
2.4. BSA-fructose assay 
The extracts were evaluated for their anti-glycation effects using the BSA-fructose assay 
based on previously reported methods by our laboratory (Liu et al., 2014; Ma et al., 
2015). Briefly, 100 µg/mL of each extract was added to the glycation reaction mixture 
containing 10 mg/mL BSA and 100 mM D-fructose and incubated at 37 °C for 21 days. 
The intrinsic fluorescence of each sample was measured at excitation and emission 
wavelengths of 360 nm and 435 nm, respectively. The synthetic anti-gycating agent, 
aminoguanidine (AG), at an equivalent concentration of 100 µg/mL, served as the 
positive control.  
2.5. BSA-MGO assay  
The extracts were evaluated for their inhibitory effects on carbonyl species induced 
AGEs formation using a reaction model containing BSA (10 mg/mL), MGO (5 mM), 
and sample (100 µg/mL) as previously reported by our laboratory (Sun et al., 2016). 
Each sample was measured for intrinsic fluorescence after 7 days incubation at 37 °C 
with excitation and emission wavelengths of 360 nm and 435 nm, respectively. The 
aforementioned wavelengths were found optimal for the detection of MGO derived 
AGEs. The positive control, AG, was evaluated at an equivalent concentration of 100 
µg/mL. 




The extracts were measured for their trapping capacity of RCS as previously reported 
by our laboratory (Liu et al., 2014).  Briefly, each reaction solution contained MGO (5 
mM), and test sample (100 µg/mL), or the positive control, AG (1000 µg/mL), and the 
mixtures were incubated at 37 °C for 4 hours. Afterwards, the derivatization reagent, 
PD (20 mM), and internal standard, DQ (5 mM), in 0.1 M phosphate buffer, pH 7.2 
were added to the reaction mixture, and the remaining MGO was quantified by HPLC-
DAD. The percentage decrease of MGO was calculated using the following equation: 
MGO decrease % = [1 - (MGO amounts in solution with tested sample/MGO amounts 
in control solution)] x 100%.  
2.7. Thioflavin T assay   
The thioflavin T (ThT) assay was used to measure the inhibitory effects of the extracts 
on Aβ1-42 fibrillation as previously reported by our laboratory (Yuan et al., 2015). In 
each sample, the final concentrations of Aβ1-42 and test sample were adjusted to 50 µM 
and 100 µg/mL, respectively. Resveratrol (RESV; at 100 µg/mL) served as the positive 
control. To induce Aβ1-42 fibrillation, two individual protocols were followed. In the 
thermo induced fibrillation assay, Aβ1-42 solutions at a concentration of 50 µM were 
incubated at 37 °C for 72 hours with or without the herbal extracts. In the MGO-induced 
fibrillation assay, 1 mM MGO was added to the reaction mixture and all samples were 
incubated at 37 °C for 72 hours. Before and after incubation, 100 µL of each sample 
was added to an equal volume of ThT solution (50 µM) and fluorescence was measured 
on a plate reader (SpectraMax M2, Molecular Devices Corp., Sunnyvale, CA, USA) at 
excitation and emission wavelengths of 450 nm and 490 nm, respectively. 




In this assay, each extract was evaluated for its inhibitory effect against Aβ1-42-AGE 
formation induced by methylglyoxal (MGO), a reactive carbonyl species. Briefly, 50 
µM Aβ1-42 solution was mixed with 1 mM MGO to produce Aβ1-42-AGEs following 
published methods (Li et al., 2013). Treatments included either 100 µg/mL of each 
extract or 100 µg/mL of the positive control, AG. After 72-hour incubation at 37 °C, the 
Aβ1-42-AGEs level was measured by intrinsic fluorescence using a plate reader 
(SpectraMax M2, Molecular Devices Corp., Sunnyvale, CA, USA) at excitation and 
emission wavelengths of 360 and 435 nm, respectively. 
2.9. Acetylcholinesterase (AChE) inhibition assay 
The AChE inhibitory activities of the herbal extracts were evaluated using a published 
spectrophotometric method with slight modifications (Ellman et al., 1961). Briefly, a 
reaction mixture consisting of 100 μL of 100 mM Tris-HCl buffer (pH 8.0), 20 μL AChE 
enzyme solution (0.5 U/mL) and 20 μL of test samples (concentration ranging from 25 
- 300 μg/mL in 100 mM Tris-HCl buffer containing 50% methanol) was co-incubated 
in the dark at 37 °C for 20 minutes in a 96-well plate. Next, 40 μL of 0.75 mM DTNB 
and 20 μL of 1.5 mM ATCI were added to the reaction mixture and incubated at room 
temperature for 5 min in the dark. Then the absorbance was measured at a wavelength 
of 405 nm using a plate reader (SpectraMax M2, Molecular Devices Corp., Sunnyvale, 
CA, USA). A 50% methanol in 100 mM Tris-HCl buffer served as the blank control 
and galanthamine, a known AChE inhibitor, served as the positive control. Each sample 
(at each concentration) was also tested without enzyme as background for the inherent 
color present in each sample. Inhibition of AChE was calculated as: % Inhibition = [1-
(Asample - Abackground )/Ablank] × 100. 




Murine microglial BV-2 cells were a kind gift from by Dr. Grace Y. Sun (University of 
Missouri at Columbia, MO, USA) and human neuronal SH-SY5Y cells were obtained 
from American Type Culture Collection (ATCC, VA, USA). The cells were maintained 
using high glucose (4.5 g/L) DMEM/F12 supplemented with 10% heat inactivated FBS, 
1% P/S (100 U/ml penicillin, 100 μg/mL streptomycin (Life Technologies, 
Gaithersburg, MD, USA) and incubated in 5% CO2 at 37 °C. All test samples were 
dissolved in DMSO to yield a 10 mg/mL stock solution and further diluted with media 
to yield final solutions with DMSO < 0.1%. 
2.11. Cell viability  
Cellular viability was assessed using the Cell Titer Glo 2.0 (CTG 2.0) one step assay 
(Promega). Briefly, the murine BV-2 microglial cells were seeded at 100,000 cells/mL 
in a standard white walled clear bottom 96-well plate.  After a 24-hour incubation 
period, CTG 2.0 was added in and mixed for 2 minutes on an orbital shaker prior to 
luminescence measurement on a plate reader (SpectraMax M2, Molecular Devices 
Corp., Sunnyvale, CA, USA).  
2.12. Quantification of nitric oxide species (NOS) by the Griess assay  
The murine BV-2 microglial cells, in 24-well plates (n=4) at 85% confluency (105 
cells/well, were serum-starved for 4 hours prior to the treatments. The cells were then 
incubated with test samples (10 μg/mL) or the positive control, resveratrol (RESV; 5 
μg/mL) for 1 hour after which inflammation was induced by lipopolysaccharide (LPS). 
Cells were incubated for 23 hours and the culture media were collected and centrifuged. 
The supernatants were measured for total nitric oxide species (NOS) by the Griess assay 





2.13. In vivo Caenorhabditis elegans assay 
The in vivo neuroprotective effects of the extracts were evaluated using a 
Caenorhabditis elegans assay as previously reported by our group with minor 
modifications (Yuan et al., 2015). Transgenic Caenorhabditis elegans (CL4176) were 
obtained from the Caenorhabditis Genetics Center (University of Minnesota, 
Minneapolis, MN, USA). This strain expresses a heat-induced human Ab1-42 gene in the 
muscle tissues and prolonged expression of the gene leads to paralysis and death. The 
stock culture was maintained at 18 °C on Nematode Growth Medium (NGM) plates 
(1.7% Agar, 0.3% NaCl, 0.25% peptone, 1 mM CaCl2, 1 mM MgSO4, 5 mg/L 
cholesterol, and 2.5 mM KPO4). NGM plates were seeded with 50 µL OP50 Escherichia 
coli and allowed to incubate overnight at 37 °C. Before seeding of the plates, the E. coli 
cultures were treated with the herbal extracts or vehicle control (0.05% DMSO). Once 
the age of the worms were synchronized to reach the L3 stage, they were placed in a 25 
°C incubator for 20 hours to induce the expression of the human Ab1-42 gene. After 20 
hours the worms were counted every 2 hours for a total of 30 hours of incubation time. 
Dead worms were characterized by lack of pharyngeal pumping or movement and >100 
worms were used for each treatment. Kaplan-Meier curves and curve comparisons 
statistics were generated using GraphPad Prism software.  
2.14. Inhibition of cytotoxicity of murine BV-2 microglia and differentiated human 
SH-SY5Y neuronal cells induced by hydrogen peroxide (H2O2) 
Cellular viability was assessed using the Cell Titer Glo 2.0 (CTG 2.0) one step assay as 
previously reported by our laboratory (Ma et al., 2016). Briefly, murine BV-2 microglia 
and differentiated human SH-SY5Y neuronal cells were seeded at 100,000 cells/mL to 




BV-2 cells were exposed to the herbal extracts and resveratrol (RESV; used as the 
positive control) for 1 hour prior to exposure to 100 μM of H2O2 for 6 hours. The SH-
SY5Y cells were incubated with the extracts and RESV for 24 hours at 37°C prior to 
exposure to 100 μM of H2O2 for 6 hours.  Following incubation, CTG 2.0 was added in 
a 1:1 ratio directly to existing media and mixed for 2 minutes on an orbital shaker prior 
to luminescence measurement (SpectraMax M2, Molecular Devices Corp., Sunnyvale, 
CA, USA).    
2.15. Quantification of total tau protein levels in differentiated human SH-SY5Y 
neuronal cells 
The protein content collected from the cell culture media of differentiated SH-SY5Y 
neuronal cells were analyzed for total tau protein levels by using an enzyme linked 
immunosorbent assay (ELISA) (Thermo Fisher, Grand Island, NY, USA). The ELISA 
was performed as per the manufacturer’s protocol. The SH-SY5Y cells were initially 
plated on 100 mm dishes at a concentration of 100,000 cells/mL. Cells were then 
differentiated for 7 days using retinoic acid (10 μM) prior to treatment with test samples 
and resveratrol (RESV; used as the positive control). Once differentiated, the SH-SY5Y 
cells were exposed to vehicle control (DMSO) or the herbal extracts for 24 hours. After 
pre-treatment, the cells were then exposed to H2O2 (100 μM) for 6 hours, after which 
the cell culture media was collected, centrifuged at 10,000 rpm for 5 minutes and 
assayed for total tau protein levels.  
2.16. Statistical Analysis 
Unless otherwise indicated, all assays were performed in triplicate and all data were 
expressed as the mean ± standard deviation (n=3). Significance was analyzed by one-




were considered as significant. In the BSA-fructose, BSA-MGO, and ThT assays, the 
inhibition rate (% inhibition) was defined using the following equation: % inhibition = 
[1-(fluorescence intensity of solution with treatment/fluorescence intensity of control 
solution)] x 100%.  
Using a similar approach as previously reported (Seeram et al., 2008), an index score 
from each individual assay was determined by assigning an index value of 100 to the 
best score for each test, and then scores for the other samples were calculated using the 
following formula: [(sample score/best score) × 100]. The average of the 
chemical/biochemical assays for each extract was then taken for the initial 
neuroprotective potential index (Table 2). Similarly, the final neuroprotective potential 
index was determined by the average of the test scores from the in vitro (in BV-2 cells), 
AChE inhibitory, and in vivo C. elegans assays using the aforementioned formula 
(Table 4). Figure 1 shows the algorithm used to derive the overall index scores for the 














3.0 Results and Discussion  
 
3.1. Total polyphenol content and antioxidant capacities  
The herbal extracts were first evaluated for their total polyphenol contents and 
antioxidant activities (DPPH and FRAP assays) since several natural plant antioxidants, 
for example, resveratrol (RESV; from grapes) and curcumin (from the Indian turmeric 
Curcuma longa spice) have been reported to show promising neuroprotective effects 
against AD (Li et al., 2012; Lim et al., 2001). As shown in Table 1, the twenty-three 
medicinal plant extracts were evaluated for their phenolic content by the Folin-Ciocalteu 
method based on gallic acid equivalents (GAEs). The total polyphenol contents ranged 
from 1.0 to 41.2% (w/w, based GAEs) and this wide range was attributed to the diverse 
types (hydrophilic vs. lipophilic) of chemical constituents found in these various 
extracts.  As expected, among the extracts, two well-known polyphenol-rich plants, 
Punica granatum (41.2%) and Phyllanthus emblica (38.9%) showed the highest 
polyphenol contents followed by Ocimum tenuiflorum (37.1%), Mucuna pruriens 
(37.0%) and C. longa (31.5%). Similarly, as expected, the extracts with highest 
polyphenol contents also showed the strongest antioxidant activities in both the DPPH 
and FRAP assays (see Table 1).  For example, the most potent antioxidant extracts in 
the DPPH assay were P. emblica, P. granatum and M. pruriens, which had IC50 values 
of 11.1, 13.7 and 22.4 μg/mL, respectively, followed by Cinnamomum cassia (IC50 68.9 
μg/mL), O. tenuiflorum (IC50 72.5 μg/mL), Pterocarpus marsupium (IC50 73.9 μg/mL) 
and Terminalia arjuna (IC50 84.3 μg/mL). All of these extracts showed superior 
antioxidant activity compared to the positive control, BHT (butylated hydroxytoluene), 
a synthetic commercial antioxidant (IC50 493.6 μg/mL). The antioxidant data obtained 




DPPH assay. For example, at a concentration of 100 µg/mL, P. emblica showed the 
highest FRAP capacity (2405.7 AAE/mg), followed by M. pruriens (2269.2 AAE/mg) 
and P. granatum (2032.9 AAE/mg). Other herbal extracts which showed moderate 
FRAP capacity were P. marsupium (774.9 AAE/mg), O. tenuiflorum (754.5 AAE/mg), 
Mangifera indica (695.5 AAE/mg), T. arjuna (652.2 AAE/mg), and Syzygium cumini 
(502.0 AAE/mg). 
3.2. Anti-glycation and reactive carbonyl species (RCS) scavenging capacities 
Next, the extracts were evaluated for their anti-glycative abilities and reactive carbonyl 
species (RCS) scavenging activities using three individual assays. First, the BSA-
fructose assay was used to evaluate the inhibitory effects of the extracts on total AGEs 
formation, Second, the BSA-methylglyoxal (BSA-MGO) assay was used to evaluate 
the inhibitory effects of the extracts on RCS induced AGE formation, typically seen at 
the middle stage of glycation (Wu and Yen, 2005). Third, the extracts were evaluated 
for their direct scavenging capacity on methylglyoxal (MGO) using the MGO-trapping 
assay.  
As shown in Figure 2A, all twenty-three extracts (100 μg/mL) showed anti-AGEs 
effects which ranged from 15.1 to 90.8% in the BSA-fructose assay.  Among all of the 
extracts, P. granatum showed the highest inhibition of 90.8%, which was significantly 
higher than the positive control, AG (67.2%), a synthetic anti-glycative agent. Extracts 
of P. emblica (85.3%) and Moringa oleifera (75.6%) also showed anti-AGE effects 
superior to AG. Additionally, several other extracts showed more than 50% inhibitory 
effects including O. tenuiflorum (65.3%), Foeniculum vulgare (57.4%), M. pruriens 





We then evaluated these herbal extracts for their inhibitory effects on MGO induced 
AGEs formation. As shown in Figure 2B, P. emblica and P. granatum extracts were 
the most potent inhibitors of AGE formation (i.e. 74.1% and 48.7% respectively), 
superior to AG at an equivalent concentration of 100 µg/mL (44.4%). These extracts 
were followed by C. longa (46.4%), P. vulgare (38.8%), C. asiatica (38.8%), P. 
marsupium (37.2%), O. tenuiflorum (36.9%), T. cordifolia (35.7%), and T. arjuna 
(34.7%) which were comparable to the positive control, AG (44.4%). 
In addition to the anti-glycative effects of the extracts, their MGO scavenging capacity 
may also contribute to their potential neuroprotective effects. Therefore, the MGO 
trapping ability of the extracts were evaluated as shown in Figure 2C.  At a 
concentration of 100 μg/mL, extracts of C. longa, P. granatum, and P. emblica 
scavenged MGO by 99.0, 87.3, and 78.6%, respectively. This trend was similar to the 
BSA-MGO assay wherein these extracts also showed the highest inhibition levels on 
MGO induced glycation. The extracts of M. oleifera, O. tenuiflorum, Bacopa monnieri, 
Tamarindus indica and F. vulgare also showed strong scavenging activities yielding 
MGO quenching levels ranging from 55.9 to 35.0%. Notably, the positive control, AG, 
a known MGO scavenging agent, showed 95.7% MGO trapping ability but at a much 
higher concentration of 1000 μg/mL.  
In summary, the anti-glycation activities of the most potent AGE inhibitors were P. 
granatum, P. emblica, and C. longa which were attributed to their strong antioxidant 
and MGO scavenging activities. The anti-AGEs effects of P. granatum is in agreement 
with our previously reported study (Liu et al., 2014). 




Numerous studies have shown that certain forms of Aβ, such as fibrillated Aβ and 
glycated Aβ (Aβ-AGEs) are more toxic than its native counterpart (Butterfield, 2002; 
Koo et al., 1999; Li et al., 2013). Therefore, we evaluated the twenty-three medicinal 
plant extracts for their inhibitory effects on the formation of fibrillated Aβ and glycated 
Aβ, two common targets for AD treatment. 
 The ThT binding assay was used to evaluate the fibrillation level of human Aβ1-42. In 
the thermo-induced fibrillation assay, Aβ1-42 fibril formation was confirmed by a 
significant increase in ThT fluorescence after 72 hours incubation at 37 °C. The 
fluorescence levels of Aβ treated with the extracts were then compared with the control 
and their inhibition levels on Aβ fibrillation are shown in Figure 3A. Upon treatment 
with the extracts, the lowest fibrillation level was seen in Aβ solution treated with B. 
monnieri (63.3% inhibition), followed by P. granatum (61.7% inhibition), P. 
marsupium (53.7% inhibition), P. emblica (47.9% inhibition) then C. longa (47.2% 
inhibition). The inhibition levels of these extracts were all significantly higher than 
positive control resveratrol (RESV, 31.8% inhibition), a natural phenolic compound 
known for its anti-amyloidosis and neuroprotective effects (Feng et al., 2009; Li et al., 
2012).  
Next, the herbal extracts were evaluated for their inhibitory abilities on MGO-induced 
Aβ1-42 fibrillation using the ThT binding assay. Studies have shown that reactive 
carbonyl species (RCS) such as MGO can induce Aβ fibrillation and aggregation (Chen 
et al., 2007; Chen et al., 2006). Consequently, carbonyl stress conditions with elevated 
RCS levels play an important role in the progression of neurodegenerative diseases 
including AD. Therefore, the inhibitory effects of the extracts against MGO-induced Aβ 




the highest inhibitory effect was observed in samples treated with B. monnieri (63.5%) 
and C. asiatica (62.6%), with effects significantly higher than the positive control, 
RESV (32.1%). In addition, extracts of P. granatum (49.9%), P. marsupium (39.1%), 
Boswellia serrata (37.9%) and P. emblica (33.7%) also showed inhibitory effects 
against Aβ1-42 fibrillation superior to the positive control, RESV (32.1%). 
Besides fibrillated Aβ, glycated Aβ (Aβ-AGEs) produced from the modification of Aβ 
by sugars and sugar metabolites also exacerbates the neurotoxicity of native Aβ (Li et 
al., 2013). Therefore, we next evaluated the inhibitory effects of the herbal extracts on 
the formation of glycated Aβ (Aβ-AGEs). As shown in Figure 3C, the positive control, 
AG, at a concentration of 100 µg/mL, reduced glycated Aβ formation by 58.9%. Among 
the extracts, T. arjuna showed the highest inhibition (83.8%) followed by P. emblica 
(83.2%), and P. granatum (77.7%). Several other extracts also showed inhibition levels 
superior to the positive control, AG, including T. indica (77.1%), S. cumini (76.2%), 
and Salacia reticulata (75.5%) extracts.  
Based on the data obtained from these six bioassays, namely, total polyphenol content, 
anti-oxidant capacity (DPPH and FRAP assays), anti-glycation effects, MGO trapping 
activity, Aβ fibrillation inhibition, and Aβ-AGEs inhibition, index scores were 
generated for each extract as previously reported (Seeram et al., 2008) and these results 
are summarized in Table 2. Extracts of P. granatum and P. emblica showed the highest 
score (91 and 90, respectively), followed by M. pruriens (70), C. longa (59) and C. 
asiatica (57). The medicinal plant extracts with a neuroprotective potential index score 
≥ 40, namely, the top twelve candidates, were selected for further evaluations for their 
neuroprotective potential using in vitro (BV-2 cells), AChE inhibitory, and in vivo 




3.4. Inhibition of acetylcholinesterase (AChE) enzyme activity 
Inhibitors of the acetylcholinesterase (AChE) enzyme are currently used as treatments 
for mild to moderate AD in human subjects (Birks et al., 2000) and this assay is widely 
used to screen for candidates with anti-AD potential (Birks, 2006).  Therefore, the 
medicinal plant extracts (see Table 2) which had a neuroprotective potential index score 
≥ 40 (from the initial set of bioassays described in Sec. 3.1 -3.3) were next evaluated for 
their inhibitory effects on the AChE enzyme. As shown in Table 3, the top four 
candidates namely, M. pruriens, P. emblica, P. granatum, and C. longa showed AChE 
inhibitory effects of 48.1, 43.1, 35.1, and 11.3% at 100 μg/mL, respectively, with IC50 
values ranging from 91.3 to 304.6 μg/mL.  In addition, among the twelve herbal extracts, 
T. arjuna also showed inhibitory effects against the AChE enzyme with an IC50 value 
of 313.6 μg/mL (Table 3).  
3.5. Inhibition of lipopolysaccharide (LPS)-induced nitric oxide species (NOS) 
production in murine BV-2 microglial cells 
The medicinal plant extracts (see Table 2) which had a neuroprotective potential index 
score ≥ 40 (from the initial set of bioassays described in Sec. 3.1 -3.3) were next 
evaluated for their effects on LPS-induced neuroinflammation in an established in vitro 
murine BV-2 microglia cell model. As shown in Figure 4, seven of these extracts 
inhibited NOS levels at 10 μg/mL. The most active extracts were P. marsupium and C. 
cassia, which reduced NOS production by 23.6 and 22.2%, respectively. Also, C. 
asiatica, C. longa, P. emblica, P. granatum, and B. monnieri suppressed NOS 
production by 20.8, 19.4, 19.0, 16.7 and 15.0%, respectively. The extracts of M. 
pruriens, O. tenuiflorum, and M. oleifera did not significantly reduce NOS production 




control, RESV (10 μg/mL), showed a 38.6% reduction of NOS production in the LPS-
stimulated BV2 cells. 
3.6. Reduction on Aβ1-42 induced neurotoxicity and paralysis in Caenorhabditis 
elegans  
Next, the twelve extracts (which had a neuroprotective potential index score ≥ 40 as 
described above) were evaluated using an in vivo model using a transgenic C. elegans 
strain (CL4176) as previously reported by our group (Yuan et al., 2015).  The CL4176 
strain has a mutation of human Aβ1-42 expression in the muscle of the worms and the 
deposition of Aβ1-42 leads to neurotoxicity and paralysis. As shown in Figure 5, the heat 
shock induced Aβ1-42 neurotoxicity decreased the survival rate of C. elegans to 15.3% 
at 30 hours. However, among the extracts, P. emblica, P. granatum, M. pruriens, and 
C. longa significantly increased the survival rate of C. elegans to 47.8, 45.8, 44.1, and 
39.1%, respectively. Several of the other extracts including P. marsupium, C. cassia, M. 
oleifera, B. monnieri, and O. tenuiflorum increased the survival rate of C. elegans from 
33.3 to 16.7% while S. reticulata and T. arjuna did not show any neuroprotective effects 
with a survival rate of C. elegans of 6.7 and 4.8%, respectively. Based on the results 
from the C. elegans lifespan assay, P. emblica, P. granatum, M. pruriens, and C. longa 
were ranked among the top extracts which is in agreement with the ranking obtained 
from the in vitro BV-2 cell assay, wherein C. longa, P. emblica, P. granatum, and M. 
pruriens were also the most active extracts.  
3.7. Evaluation of herbal extracts against H2O2 induced cytotoxicity in murine BV2 
microglia and human neuronal SH-SY5Y cells 
It is well established that oxidative stress is linked with the pathology of several 




Therefore, based on the bioassays described in Sec. 3.4 -3.6, a final neuroprotective 
potential index score was calculated (see Table 4) and the extracts which had an index 
score ≥ 60, namely, P. granatum, P. emblica, M. pruriens and C. longa, were selected 
for further evaluation of their neuroprotective effects against H2O2 induced cytotoxicity 
in murine BV-2 microglia and differentiated human SH-SY5Y neuronal cells.  As 
shown in Figure 6A, the cell viability of the H2O2-treated murine microglial BV-2 cells 
decreased by 31.7% as compared to the control group.  When the H2O2-exposed cells 
were subsequently treated with the herbal extracts (concentration of 10 µg/mL), M. 
pruriens, P. emblica, P. granatum, and C. longa increased cell viability by 30.2, 22.3, 
12.3, and 5.6%, respectively, as compared to the cells exposed to H2O2 alone. Similarly, 
as shown in Figure 6B, the cellular viability of H2O2-treated human neuronal SH-SY5Y 
cells decreased by 48.2% as compared to the control group. When the H2O2-exposed 
cells were subsequently treated with the herbal extracts (each at a concentration of 10 
µg/mL), C. longa, M. pruriens, and P. emblica significantly increased the cell viability 
by 109.1, 90.6, and 76.9%, respectively. Resveratrol (RESV), which served as the 
positive control, also increased cell viability of H2O2-treated murine BV-2 microglia 
(19.5%) and differentiated human SH-SY5Y neuronal (79.3%) cells (Figure 6).  
3.8. Evaluation of herbal extracts on tau protein production in differentiated 
human SH-SY5Y neuronal cells 
Studies have shown that in neurodegenerative models, including AD, neurons 
undergoing cell stress release tau proteins which on hyperphosphorylation form 
neurofibrillary tangles which can ultimately lead to cell death (Gomez-Ramos et al., 
2006). Therefore, as described above (see Section 3.7), the extracts which had an index 




for further evaluation of their inhibitory effects on tau protein production in human 
neuronal SH-SY5Y cells. As shown in Figure 6C, extracts of C. longa, P. granatum, 
M. pruriens, and P. emblica reduced extracellular tau protein levels by 83.7, 82.6, 66.4, 




4.0 Conclusions  
 
 In summary, using bioassays with established links between AD and oxidative stress, 
carbonyl stress, glycation, Aβ fibrillation, Aβ-AGE formation, AChE inhibition, and 
neuroinflammation, an AD Neuroprotective Potential Algorithm (NPA) was developed 
as part of a strategy to help guide the selection and evaluation of medicinal plant 
candidates for future AD based research. From the current study, four extracts identified 
with a cumulative neuroprotective potential index score ≥ 60 were Phyllanthus emblica 
(amla; Indian gooseberry), Mucuna pruriens (velvet bean), Punica granatum 
(pomegranate) and Curcuma longa (curcumin; turmeric). Interestingly, published 
animal data support the neuroprotective effects of two of these extracts namely, P. 
granatum (Yuan et al., 2015; Ahmed et al., 2014) and C. longa (Ringman et al., 2005) 
against AD. While the other two extracts remain underexplored for their anti-AD 
potential, P. emblica has been shown to improve memory deficits in mice (Ashwlayan 
and Singh, 2011) and M. pruriens has been shown to have protective effects against 
Parkinson’s disease in human subjects (Katzenschlager et al., 2004).  
There are several limitations to the NPA developed herein, primarily, due to the fact 
that botanical extracts are complicated mixtures containing multiple ‘multi-targeting’ 
phytochemicals which undergo complex metabolic processes in vivo (including 
metabolism by the liver enzymes and gut microflora) which influence their 
bioavailability, metabolism, excretion, and generation of ‘further’ bioactive metabolites 
(Wang et al., 2015; Yuan et al., 2015; Wang et al., 2014).  For example, our group has 
recently reported that the gut microbial metabolites produced from the colonic 
microflora metabolism of the natural ellagitannins present in the pomegranate (P. 




effects reported for this natural product (Yuan et al., 2015). Therefore, a major limitation 
of the NPA developed here is the lack of critical in vivo data (accumulated from animal 
models) which would account for the aforementioned important physiological 
considerations (Singh et al., 2008; Ebrahimi and Hermann, 2012). Other limitations of 
the NPA include utilizing additional AD-targeted bioassays and its validation with an 
increased sample size of medicinal plant extracts and their combinations thereof.  
Nevertheless, given all of these limitations, the NPA may be utilized in consideration 
with published literature data (when available) of animal and human studies, traditional 
and ethnomedicinal use, etc., as part of a more comprehensive research strategy to guide 
the selection of promising medicinal plant candidates for future AD based research 
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Figure 1. Neuroprotective Potential Algorithm (NPA) for selecting and evaluating 
medicinal plants as potential candidates for Alzheimer’s disease based research. 
 
STEP 1: Measure antioxidant capacity (Table 1) 
-   Total polyphenol content (Folin-Ciocalteu assay) 
-   Free radical scavenging (DPPH assay) 
-   Ferric reducing antioxidant power (FRAP assay) 
 
STEP 2: Measure inhibitory effects on glycation (Figure 2) 
-    Fructose-induced AGEs formation 
-    Carbonyl species (MGO)-induced AGEs formation 
-    MGO trapping ability 
 
STEP 3: Measure inhibitory effects on Aβ fibrillation (Figure 3) 
-    Thermo-induced Aβ fibrillation 
-    Carbonyl species (MGO)-induced Aβ fibrillation 
-    Aβ-AGEs formation 
 
Ø Obtain initial neuroprotective potential index (Table 2) 
Ø Select candidates with score ≥ 40 (modifiable)  
 
STEP 4: Measure inhibitory effects on AChE activity (Table 3) 
 
STEP 5: Measure in vitro inhibitory effects on neuroinflammation 
(Figure 4) 
-    Nitric oxide species (NOS) production in murine BV-2 microglia cells 
 
STEP 6: Measure in vivo neuroprotective effects (Figure 5) 
-    Aβ
 
induced paralysis in Caenorhabditis elegans 
 
Ø Obtain final neuroprotective potential index (Table 4) 









Figure 2. Inhibitory effects of medicinal plant extracts (100 µg/mL) on D-fructose 
induced BSA AGEs formation (A), MGO induced BSA AGEs formation (B) and MGO 





Figure 3. Inhibitory effects of medicinal plant extracts (100 µg/mL) on thermo-induced 
Aβ fibrillation (A), MGO induced Aβ fibrillation (B) and MGO induced Aβ-AGEs 
formation (C). Resveratrol at 100 µg/mL served as the positive control for Aβ 
fibrillation studies (A and B) while aminoguanidine at 100 µg/mL served as the positive 





Figure 4. Anti-neuro-inflammatory effects of medicinal plant extracts on murine BV-2 
cells microglial cells by measuring NOS production induced by LPS. BV-2 cells were 
treated with each extracts (10 μg/mL) for 1 h followed by exposure to LPS (1 μg/mL) 
for 24 h. The cell culture media were used to assay the amount of NOS production by 





Figure 5. Protective effects of medicinal plant extracts against neurotoxicity and 
paralysis in Caenorhabditis elegans in vivo.  Mobility curves of transgenic (CL4176) 
C. elegans 30 hours post Aβ1-42 induction of muscular paralysis at 25 °C. Kaplan-Meier 
mobility plots of C. elegans worms fed on twelve extracts [Control (NGM), in dot line; 





Figure 6. Protective effects of medicinal plant extracts (10 µg/mL) on H2O2 induced 
cytotoxicity in murine BV-2 microglia (A) and differentiated human SH-SY5Y 
neuronal cells (B). Cellular viability was assessed using Cell Titer Glo 2.0 (CTG 2.0) 
one step assay. C: Inhibitory effects of medicinal plant extracts (10 µg/mL) on tau 
protein levels in differentiated SH-SY5Y neurons (C). All data are presented as mean 




Table 1. Medicinal plants and their total polyphenol contents and antioxidant activity 
(DPPH and FRAP assays) 
















Bacopa monnieri Waterhyssop enhance memory 
Whole 











ers Fruit 2.9 ± 0.7 n.a. 
 
n.a. 
Centella asiatica Gotu kola antidiabetic 
Whole 










Curcuma longa Turmeric, Curcumin 
anti-






Foeniculum vulgare Fennel 
anti-










Mangifera indica Mango 
clearing 










Mucuna pruriens Velvet bean 
neurodegenerati








Phyllanthus emblica Amla 
anti-
























































a(w/w % as of gallic acid equivalents); bvalue = IC50 (μg/mL), n.a. = not active (IC50 
>2000 μg/mL); cn.d. = not detected; cvalue = ascorbic acid equivalents/mg dry plant 




Table 2. Initial screening for neuroprotective potential index based on total polyphenol 
content, antioxidant, anti-glycation, and anti-Aβ fibrillation activities 
 
aBSA AGEs formation induced by D-fructose; bBSA AGEs formation induced by 
methylglyoxal (MGO); cthermo induced Aβ fibrillation (37 °C); dMethylglyoxal (MGO) 


























1 P. granatum 100 99 85 100 100 66 93 79 97 91 
2 P. emblica 95 100 100 90 94 100 99 53 76 90 
3 M. pruriens 90 95 94 85 61 39 63 43 63 70 
4 C. longa 77 52 17 99 41 63 71 37 75 59 
5 C. asiatica 66 67 9 23 57 52 74 99 63 57 
6 P. marsupium 50 59 32 3 60 50 76 62 83 53 
7 C. cassia 55 87 13 12 43 42 56 45 57 46 
8 O. tenuiflorum 90 63 31 45 72 50 50 0 1 45 
9 T. arjuna 60 56 27 22 47 47 100 25 8 44 
10 B. monnieri 8 3 4 45 35 37 49 100 100 42 
11 M. oleifera 49 32 5 64 83 40 7 49 43 41 
12 S. reticulata 56 22 17 11 42 30 90 41 64 41 
13 S. cumini 52 53 21 0 21 18 91 30 26 35 
14 F. vulgare 59 35 7 40 63 52 40 0 0 33 
15 T. indica 9 41 3 43 48 42 92 11 0 32 
16 W. somnifera 63 36 7 10 38 41 81 7 0 31 
17 T. cordifolia 21 38 10 16 56 48 89 0 0 31 
18 M. indica 68 68 29 11 42 44 0 19 0 31 
19 G. sylvestre 51 43 11 13 26 23 38 28 8 27 
20 A. indica 31 21 8 0 26 23 79 13 32 26 
21 S. indicum 2 1 3 25 47 40 46 30 17 23 
22 B. serrata 6 7 0 14 19 18 34 60 46 23 




Table 3. Inhibitory effects on AChE activity of selected medicinal herbal extracts (top 
12 based on initial screening) 
 




P. granatum 35.06 ± 2.93  304.62 ± 1.27 
P. emblica 43.11 ± 1.72 163.92 ± 3.55 
M. pruriens 48.11 ± 2.78 91.35 ± 2.80 
C. longa 11.31 ± 1.81   ─ b 
C. asiatica  n.a. a ─ 
P. marsupium n.a. ─ 
C. cassia n.a. ─ 
B. monnieri n.a. ─ 
O. tenuiflorum n.a. ─ 
M. oleifera n.a. ─ 
T. arjuna 12.88 ± 2.58 313.58 ± 6.21 
S. reticulata 7.64 ± 1.43 ─ 
galanthamine c 68.50 ± 1.10 5.37 ± 3.79 
 
a n.a. = not active; shown as mean values ± SD (n ≥ 3). b ─, > 600 μg/mL. c Used as 




Table 4. Final screening for medicinal plant extracts for neuroprotective potential index 
based on the AChE inhibitory activity assay, in vitro anti-neuro-inflammatory effects in 
murine BV-2 microglial cells, and in vivo neuroprotective effects against Aβ1-42 induced 
neurotoxicity and paralysis in C. elegans 











1 P. emblica 90 80 100 90 
2 M. pruriens 100 49 96 82 
3 P. granatum 73 71 96 80 
4 C. longa 23 82 82 62 
5 P. marsupium 0 100 60 53 
6 C. asiatica 0 88 70 53 
7 C. cassia 0 94 42 45 
8 B. monnieri 0 64 38 34 
9 O. tenuiflorum 0 27 35 21 
10 M. oleifera 0 19 42 20 
11 S. reticulata 8 0 14 7 
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Phenolic compounds isolated and identified from Amla (Phyllanthus emblica) juice 
powder and their antioxidant and neuroprotective activities. Rose, Kenneth N.; Wan, 
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  Abstract 
The edible fruit of Phyllanthus emblica (known as amla and Indian gooseberry) is 
widely used in Eastern traditional medicinal systems for a variety of ailments. Our 
group has previously reported that an amla juice powder shows neuroprotective 
effects in several in vitro and in vivo assay models but its chemical constituents and 
their neuroprotective activity remain unknown. Therefore, we conducted a 
phytochemical investigation of amla juice powder and evaluated the antioxidant and 
neuroprotective effects of the isolates. Ten phenolics (1-10), including gallic acid (1), 
five gallic acid derivatives (2-6), ellagic acid (7), and three ellagic acid derivatives 
(8-10), were isolated and identified with compounds 8-10 being reported from amla 
for the first time. All of the isolates showed antioxidant effects in the DPPH assay 
with IC50 values ranging from 6-158.9 µM superior to the synthetic commercial 
antioxidant, butylated hydroxytoluene (IC50 = 371.4 µM). In addition, compound 8 
reduced β-amyloid-induced neurotoxicity in a transgenic Caenorhabditis elegans 
model by increasing their survival rate by 28.3% compared to the control group. This 
study adds to the growing body of evidence supporting the potential health benefits 





1.0 Introduction  
Amla (Phyllanthus emblica), also known as Indian gooseberry, is a deciduous tree that 
commonly grows in the subtropical and tropical regions of Southeast Asia including 
southern India and China. Various parts of the amla plant, especially its fruit, are 
traditionally used as folk remedies for numerous ailments in traditional Chinese and 
Indian (Ayurvedic) medicinal systems [1, 2]. Previous phytochemical studies reported 
that the major bioactive compounds present in amla fruits are phenolics including 
hydrolyzable tannins (both ellagitannins and gallotannins), anthocyanins, flavonoids, 
flavonols, and phenolic acids [2-6]. While amla fruits are regionally consumed as a 
food and spice, because of seasonal factors and perishability, the fruits are only 
available for a short period. Therefore, an amla juice powder is a viable option to 
preserve the fruit’s bioactive constituents for nutraceutical and functional beverage 
applications. Our laboratory has reported on the development of a neuroprotective 
potential algorithm (NPA) to screen medicinal plant extracts in which an amla juice 
powder ranked top among twenty Ayurvedic medicinal plants [7]. However, whether 
the bioactive compounds present in this particular amla juice powder are similar or 
different from amla fruits remain unknown. 
In our continued efforts to further investigate the biological activities of the top 
ranking medicinal plants using the NPA [7], herein, we sought to isolate and identify 
the bioactive compounds from the aforementioned amla juice powder and evaluate 
their antioxidant and neuroprotective effects using assays adopted from the NPA. In 
the current study, ten phenolic compounds (1-10) were isolated from the amla juice 
powder and their chemical structures (shown in Figure 1) were identified by 




References 8-14). Ten isolates were identified as gallic acid(1) [8], methyl gallate (2) 
[9], 1-O-galloyl-glucoside (3) [10], mucic acid 3-O-gallate (4) [11], corilagin (5) [12], 
1,6-di-O-galloyl- glucoside (6) [10], ellagic acid (7) [8], ellagic acid-4-O-glucoside 
(8) [8], ellagic acid-4-O-xyloside (9) [13], and ellagic acid-4-O- rhamnoside (10) [14]. 
While compounds 1-7 have been previously reported from amla fruit [2-6], to the best 
of our knowledge, compounds 8-10 are being reported from this plant for the first time. 
The amla juice powder and its isolates were evaluated for antioxidant and anti-β-
amyloid effects in Caenhorhabditis elegans. Amla juice powder had an IC50 value of 
28.9 µg/mL in the antioxidant (DPPH) assay and compounds 1-10 showed superior 
antioxidant activities (IC50 values = 6.0, 3.1, 2.7, 1.6, 4.9, 3.0, 2.6, 73.4, 26.3, and 
158.9 µM, respectively) compared to the positive control, butylated hydroxytoluene 
(a synthetic commercial antioxidant; IC50 = 371.4 µM). The neuroprotective effects 
of the amla juice powder and compounds 1-10 were evaluated using a transgenic C. 
elegans nematode model (CL1476). Amla juice powder (at 10 µg/mL) significantly 
reduced the β-amyloid-induced neurotoxicity in the nematodes and increased their 
survival rate by 28.2% as compared to the control group (Figure 2A). Compound 8 
(at 10 µM) increased the survival rate of nematodes by 28.3% as compared to the 
control group (Figure 2B). 
None of the other isolates showed significant activity in this assay. However, further 
studies would be required to evaluate the neuroprotective effects of this amla juice 
powder and its isolated compounds. In summary, ten phenolic compounds were 
isolated and identified from an amla juice powder and their antioxidant and 




evidence supporting the potential health benefits of amla and supports the functional 




2.0 Experimental  
2.1 General 
The 1H and 13C nuclear magnetic resonance spectroscopic experiments were 
conducted in methanol (CD3OD) on a Varian 500 MHz instrument. HR-ESIMS data 
were acquired on Waters SYNAPT G2-S QTOFMS system. Solvents were either ACS 
or HPLC grade purchased from Wilkem Scientific (Pawtucket, RI, USA). High 
performance liquid chromatography (HPLC) was performed on a Hitachi Elite 
LaChrom system (Pleasanton, CA, USA) consisting of a L-2130 pump, L-2200 
autosampler, and a L-2455 diode array detector. 
2.2 Plant material 
Amla juice powder was kindly provided by Verdure Sciences (Noblesville, IN, USA) 
and voucher specimens (LEO2JP110210) are deposited in the Heber Youngken 
Herbarium and Greenhouse at the College of Pharmacy, the University of Rhode 
Island, RI, USA. 
2.3 Extraction and isolation 
Amla juice powder (20 g) was dissolved in 50 mL DI water and chromatographed on 
a XAD-16 resin column (3 × 10 inch) eluted with a gradient system of MeOH/H2O 
(0/100, 50/50 and 100/0; v/v) to afford three sub-fractions (A1-A3). Sub-fraction A2 
was separated by medium-pressure liquid chromatographic (MPLC) column (2 × 15 
cm) with C18 resin eluted with a gradient system of MeOH/H2O (10/90 to 40/60; v/v) 
to afford four sub-fractions (B1-B4). Sub-fraction B1 was separated by semi-
preparative HPLC eluted with MeOH/H2O (11/89; v/v) to yield compounds 1 (229 
mg, tR = 13.0 min), 3 (18.6 mg, tR = 8.0 min), and 4 (12.6 mg, tR = 12.0 min). Sub-




of MeOH/H2O (18/82 to 35/65; v/v) to yield compounds 2 (16.0 mg, tR = 15.16 min), 
and 6 (8.6 mg, tR = 12.58 min). Sub-fraction B3 was separated by semi-preparative 
HPLC eluted with a gradient system of MeOH/H2O (18/82 to 40/60; v/v) to yield 
compound 5 (13.1 mg, tR = 14.24 min). Fraction A3 was separated on the C18 MPLC 
column (2 × 15 cm) eluted with a gradient system of MeOH/H2O (3:7 to 8:2, v/v) to 
afford 4 sub-fractions (C1-C4). Sub-fractions C4 was separated by a Sephadex LH-20 
resin column (2 × 58 cm) eluted with MeOH to afford 3 sub-fractions (D1-D3). Sub-
fractions D2 was separated by semi-preparative HPLC eluted with a gradient system 
of MeOH/H2O (45/55 to 68/32; v/v) to yield compounds 7 (62.9 mg, tR = 17.8 min), 
8 (4.5 mg, tR = 11.6 min), 9  (3.9 mg, tR = 
15.3 min) and 10 (4.1 mg, tR = 16.3 min). 
2.4 Antioxidant activity 
The antioxidant activity was evaluated using the 2,2-diphenyl-1-picrylhydrazyl 
(DPPH) assay [15, 16]. Briefly, 100 µL of test sample (1-1000 µg/mL for amla juice 
powder and 1- 500 µM for the isolates) was mixed with 100 µL of DPPH dissolved 
in methanol (0.25 mM) in a 96-well plate. The plate was incubated at room 
temperature in the dark for 35 min and then the absorbance of each well was read at 
517 nm using a plate reader (SpectraMax M2, Molecular Devices Corp., Sunnyvale, 
CA, USA). 
2.5 In vivo anti-neurotoxicity assay (Caenorhabditis elegans assay) 
C. elegans (CL1476) were obtained from the University of Minnesota 
Caenorhabditis Genetics Center. Worms were grown on nematode growth agar in 
Petri dishes maintained at 16 C. UV-killed OP50 E. coli was plated as a food source 




hypochlorite method [7, 17]. Age synchronous C. elegans were washed from the Petri 
dish with liquid nematode growth medium. Aliquots of the washed worms were 
placed into the wells of a 96-well plate. A microscope was used to ensure that 
approximately 20 worms were placed into each well with a final volume of 100 µL 
diluting with liquid nematode growth medium. Amla juice powder (10 µg/mL) or 
each of the phenolic compounds (10 µM) was added to each well and DMSO (0.01%) 
served as vehicle control. Worms were placed at 16°C for 24 hours after treatment 
and then a baseline count of living worms was taken followed by incubation at 25°C 
for the duration of the experiment. Worms were counted every hour for 6 hours and 
considered dead if they were not moving or pumping their pharynx. Kaplan-Meier 
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 Figure 1: Chemical structures of compounds 1-10 from amla juice powder  
 
 











Figure 2: Protective effects of amla juice powder (10 µg/mL; A) and compound 8 (10 
µM; B) against neurotoxicity and paralysis in C. elegans in vivo. Kaplan-Meier 
mobility plots of C. elegans worms treated with test sample [Control (NGM), in dotted 







MOLECULAR BIOLOGY AND MASS SPECTROMETRY TECNIQUES FOR THE 
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Recently, there has been increasing interest in gut microflora’s effects on human 
health. Gut microflora may contribute to human health by the biotransformation of 
compounds found in food to metabolites that may differ significantly in terms of 
structure and bioactivity from their parent compounds. These compounds may be 
beneficial to health and particularly to brain health. Gut microbiota metabolites are 
often smaller and less polar than their parent molecules, increasing the likelihood of 
passive transport across the blood-brain barrier. Urolithins are a class of compounds 
that result from the biotransformation of ellagitannins by gut the microbiota. 
Ellagitannins are common in several edible botanical sources such as walnuts, 
pomegranates, and oak-aged beverages. Urolithins have been studied regarding cancer 
cell viability, however, recent research has suggested that urolithins have a 
neuroprotective effect as they perform well in screening assays against amyloid-b-
induced toxicity. Therefore, we hypothesized that a mechanism of action must exist to 
explain their neuroprotective effects. Using proteomics to evaluate the effects of 
urolithin treatment on protein expression and a technique known as drug affinity 
responsive target stability (DARTS) to assess protein targets of urolithins, we were 
able to demonstrate that the model compound, methylated Urolithin B, can increase 
the activity of complex I in a human neuroblastoma cell model and can inhibit the 
activity of the DNA repair protein poly ADP-ribose polymerase-1 at nanomolar 
concentrations. These mechanisms can help to explain the antiproliferative effects of 
urolithins, through PARP-1 inhibition, and possibly the neuroprotective effects 
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1.0 Introduction  
Complex I is a group of proteins that serves a vital role in the electron transport chain 
as it develops the electron gradient across the mitochondrial membrane necessary for 
the production of ATP.1 Of the five complexes within the mitochondria, complex I 
initiates the electron transport chain. Decreases in complex I activity affect the other 
constituents of the electron transport chain and therefore alters the respiration capacity 
of the mitochondria2. Deficiencies in complex I function have been linked to several 
disorders including mitochondrial diseases, neurological disorders, and inflammatory 
diseases.3,4 Therefore, restoring complex I activity to basal levels may have a 
therapeutic benefit. 
 
Urolithins are gut microbiota metabolites of ellagitannins which are found in several 
food sources such as walnuts, pomegranates, and oak-aged beverages.5 Urolithins have 
been studied heavily regarding their anti-cancer effects, particularly in colon cancer 
where urolithin concentrations are presumably at their highest concentration within the 
body.6 Several groups have identified mechanisms of action for urolithins’ anti-cancer 
effect including p21 upregulation and inhibition of EphA2 phosphorylation.7,8  
 
Recently, urolithins have been identified to have beneficial effects in inflammatory, 
neurodegenerative, and mitochondrial disease models.9,10 The mechanisms responsible 
for urolithins’ anti-cancer effects are unlikely to be responsible for the observed 
effects in other diseases models. Therefore, urolithins may be acting upon separate 
pathways not related to their anti-cancer activity that explains their efficacy in a 




mitochondria respiration capacity.9 With this knowledge, we focused our investigation 
for urolithins’ mechanism of action to the mitochondria. Herein, we demonstrate 
through several in vivo, in vitro, and advanced proteomic methods that methylated 
urolithin B (mUB), a model compound, improves oxidative stress resistance in C. 
elegans, upregulates a core component of complex I, and restores complex I activity to 
normal levels in a high oxidative stress environment. Furthermore, we assert that mUB 
induced increases in complex I activity is responsible, in part, for urolithins’ efficacy 
in non-oncology disease models.  
           
To model a broad range of diseases where oxidative stress plays a role in disease 
progression, we use Caenorhabditis elegans treated with the pro-oxidant 5-hydroxy-
1,4-naphthalenedione (juglone).11 Treatment with juglone leads to the production of 
reactive oxygen species and significantly reduces the lifespan of C. elegans. When 
juglone is co-administered with mUB, C. elegans lifespan is significantly increased 
(Figure 1). Even at mUB concentrations as low as 1µM, the lifespan of C. elegans was 
increased by approximately 20% with maximum life extension at 5µM increasing 
lifespan by 33%. Given that this model relies on the production of ROS to be 
detrimental to C. elegans lifespan, it is likely that compounds that can scavenge free 
radicals would be efficacious. However, urolithins can act as both pro- and 
antioxidants depending on the cellular context.12 Therefore, the extension of lifespan 






To determine which mechanisms are responsible for the extension of lifespan in 
juglone treated C. elegans we used LC-MS/MSall with SWATH acquisition. This data 
independent acquisition method is on the cutting edge of proteomics research and 
holds several advantages over traditional LC-MS based proteomic approaches 
including reproducibility and enhanced quantification.13 Using SWATH acquisition 
were identified 9 of the 12 C. elegans mitochondrial proteins from the UniProt 
database and created a heat map of their relative intensities (Figure 2). The protein 
NADH-ubiquinone oxidoreductase core chain 4L (NU4LM) was expressed nearly 2-
fold higher in C. elegans treated with mUB. NU4LM is a part of the minimal 
components necessary to the function of complex I which creates the electron gradient 
across the mitochondrial membrane. Mutations of complex I are correlated with the 
hereditary mitochondrial disease Leber’s optic neuropathy and mitochondrial 
encephalopathy.14,15 
 
Being a core component of complex I, we hypothesized that overexpression of 
NU4LM would increase the activity of complex I. To study the relationship between 
complex I and mUB we used human neuroblastomas, SH-SY5Y, as readily available 
kits exist for complex I activity in humans and other mammals, but not for C. elegans. 
When cells are treated with hydrogen peroxide, complex I activity is reduced to 
approximately half of its basal level. Co-administering hydrogen peroxide and mUB at 
all tested concentrations (1, 5, and 10 µM) returns complex I activity to near basal 
level (Figure 3).         




Our findings are in agreement with recently published research describing urolithin 
A’s ability to improve cellular respiration9. Increases in complex I function provide an 
explanation for this activity as short-term administration of urolithin A’s does not 
increase the number of mitochondria within a cell, but energy output increased. 
Furthermore, several of the diseases in which urolithins have been identified as being 
beneficial for such as inflammatory and neurodegenerative are possibly due, in part, to 
ROS accumulation16. As demonstrated in figure 3, excessive ROS leads to decreases 
in complex I activity and mUB restores complex I activity to near basal levels. 
Reduction in complex I activity leads to the degradation of mitochondrial membrane 
potential which initiates the cascade of cellular events leading to mitochondria induced 
apoptosis17. With this in mind, we hypothesized that mUB treatment would decrease 
the number of cells undergoing apoptosis induced by juglone. Using the stain SYTO-
12, we found that mUB at the concentration of 10µM significantly reduced the number 
of cells undergoing apoptosis (Figure 4). While the other two concentrations of 
urolithins were not statistically significant at reducing the number of apoptotic cells, 
there is a trend of apoptotic cell reduction. 
 
In summary, urolithins have several different bioactivities described in the literature. 
However, molecular mechanisms responsible for their efficacy have only been well 
described for oncology models. Until this point, few mechanisms have been identified 
that explains the efficacy in non-oncology related disease models. Using various in 
vivo and in vitro experiments along with recent advances in proteomics, we have 




activity may, in part, be responsible for the beneficial effects of mUB in a high 





2.1 C. elegans Maintenance  
Wild-type (N2) C. elegans were obtained from the Caenorhabditis Genetics Center 
(CGC) at the University of Minnesota. Worm cultures were maintained on Nematode 
Growth Medium (NGM) (1.7% Agar, 0.3% NaCl, 0.25% peptone, 1mM CaCl, 1 mM 
MgSO4, 5mg/L cholesterol in ethanol, and 2.5 mM KPO4) in petri dishes at 20°C with 
UV-killed OP50 E. coli as a food source. Age synchronous cultures were obtained by 
standard hypochlorite method18. For mUB treatment, C. elegans were washed from 
their plates with liquid nematode growth medium (0.3% NaCl, 0.25% peptone, 1 mM 
CaCl, 1 mM MgSO4, 5 mg/L cholesterol in ethanol, and 2.5 mM KPO4) and 
transferred to culture flasks containing UV-killed OP50 E. coli as a food source.  
 
2.2 Cell Culture Conditions  
SH-SY5Y (human neuroblastoma) cell lines were obtained from the American Type 
Culture Collection (ATCC) and were maintained using high glucose (4.5 g/L) 
DMEM/F12 supplemented with 10% heat inactivated FBS, 1% penicillin (100 U/mL) 
and streptomycin (100 μg/mL) and  incubated in 5% CO2 at 37°C. To harvest SH-
SY5Y, cells were trypsinized (0.25% Trypsin/ EDTA), centrifuged (1500 rpm for 5 
min) and re-suspended in 10% DMEM/F12. Cell concentration was determined by 
counting cells with a hemocytometer and viability was assessed by trypan blue 
staining. Prior to starting experiments, all-trans retinoic acid (RA) was used to 
differentiate SH-SY5Y for 7 days at a concentration of 10 μM while changing media 





2.3 C. elegans Stress Resistance Assay   
An age synchronous culture of N2 (L2) worms in liquid NGM was split into five 
culture flasks. The flasks were treated with methylated urolithin B at 1, 5, and 10 µM 
and 0.05% DMSO control. The cultures were placed on a rocker and incubated for 24 
hours. After incubation, the cultures were transferred to small Petri-dishes containing 
NGM with 400 µM Juglone. Immediately after the worms were added to their 
respective petri dishes, a baseline count was taken with a dissecting microscope. Then, 
worms were counted every hour until no surviving worms were left.20 Dead worms 
were characterized via lack of pharyngeal pumping.     
 
2.4 Staining for Apoptotic Cells in C. elegans            
An age synchronous culture of N2 (L2) C. elegans were washed from their plate with 
liquid NGM. The culture was then split into five culture flasks and treated with the 
mUB and solvent control to a concentration of 1, 5, and 10 µM and 0.05% DMSO. 
The flasks were placed on a rocker and incubated for 24 hours. The cultures were then 
incubated with 400 µM juglone for one hour; this compound induces oxidative stress 
eventually leading to death. After which time, the cultures were washed three times 
with PBS to remove the E. coli food source. The stain, SYTO-12, was added to a final 
concentration of 33 µM.21 The worms were incubated for an additional thirty minutes 
in the dark. After incubation, the worms were washed once in PBS and then 
anesthetized with 3% sodium azide in PBS and mounted onto microscope slides. 
Visualization of SYTO-12 stain was done under an EVOS microscope with an 
excitation filter of 518 nm. At least 20 worms were photographed per experimental 





2.5 C. elegans Culturing for Mass Spectrometry Analysis  
C. elegans were cultured on 100 mm plates using standard laboratory procedures. 
When the worms reach the L4 stage, the plates were washed with 5ml of PBS. The 
solution was centrifuged gently at 1,000 X g for 5 minutes to form a pellet gently. The 
pellet was washed three times with 1 mL of PBS to remove the E. coli food source. 
After the final washing, the supernatant was removed, and the pellet was suspended in 
lysis buffer and allowed to incubate on ice for 10 minutes. Next, the solution was 
centrifuged at 16,000 x g for 10 minutes at 4 C to pellet genetic material and cellular 
debris. The supernatant was removed and kept on ice until further processing.  
 
2.6 Protein Digestion Aided with Pressure Cycling Technology (PCT) 
Protein digestion was performed on C. elegans lysate according to the published 
method with modifications13.  After obtaining 500 µL of the lysate at 1 mg/mL, 80 µL 
of 100 mM DTT and 200 µL of 50 mM ABC were added and incubated for 10 min at 
95°C.  After, 80 µL of 200 mM IAA was added to the samples, vortexed and 
incubated at room temperature for 30 min in the dark.  An ice-cold mixture of 
methanol (0.5 mL), chloroform (0.25 mL) and water (0.25 mL) was then added to the 
samples to concentrate the protein.  Samples were vortexed and spun at 16,000x g for 
5 min at 4°C followed by an ice-cold methanol wash off the pellet.  The pellet was re-
suspended in 145 µL of 50 mM ammonium bicarbonate (pH 7.4), and 25 µL of TPCK 
treated trypsin (1mg/mL) was added to achieve a 1:20 trypsin ratio.  Samples were 
transferred to MicroTubes (Pressure BioSciences Inc., South Easton, MA) and placed 




perform PCT-aided digestion following a published method with modifications.  
Pressure cycling was performed for 90 cycles at 50°C.  Each cycle consisted of 50 
seconds at 35,000 psi and 10 seconds at ambient pressure.  Trypsin digestion was 
stopped by adding formic acid to achieve a final concentration of 0.1% formic acid.  
Samples were vortex and spun at 1000x g for 5 min at 10°C.  The supernatant was 
collected and transferred to 150 µL micro-inserts for analysis. 
 
2.7 LC-MS/MS Analysis  
LC-MS/MS analysis was done as previously described13.  In brief, the analysis was 
done on a Sciex 5600 TripleTOF™ mass spectrometer using a DuoSpray™ ion source 
(AB Sciex, Concord, Canada).  The mass spectrometer was coupled to an Acquity 
UPLC HClass system (Waters Corp., Milford, MA, USA) using an Acquity UPLC 
Peptide BEH C18 (2.1 X 150 mm, 300 Å, 1.7 µm) with an Acquity VanGuard pre-
column (2.1 X 5 mm, 300 Å, 1.7 µm). The injection volume was 10 µL and the 
amount of protein per injection was 30 µg.  TOF detector mass calibration was 
monitored by injecting trypsin-digested β-galactosidase peptides before and after the 
samples were run.  Chromatographic and mass spectrometric methods for both 
standard information dependent acquisition (IDA) and (SWATH-MS) data 
acquisitions are previously described.13 
 
2. 8 Data Processing with Skyline and R Studio  
SWATH-MS data was imported into Skyline (University of Washington) for analysis 
of proteins. Peptides were selected for each protein followed by peak visualization and 




were exported for comparison and heatmap generation in R-Studio using the Pretty 
Heatmap and Color Brewer Palettes packages.  
  
2.9 Complex I activity in human neuroblastomas, SH-SY5Y 
Complex I activity was measured in differentiated SH-SY5Y human neuroblastomas. 
Cells were pre-treated with vehicle control or mUB at 1, 5, or 10 µM for 24 hours. 
After which time, the cells were treated with 400 µM hydrogen peroxide for an 
additional 24 hours. Cells were harvested and washed twice in PBS. Complex I 
activity was then measured using a colorimetric complex I enzyme activity microplate 
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Figure 1. Kaplan-Meier survival curves of C. elegans treated 400µM Juglone and 








































Figure 2. Heat map of the proteins identified in the samples that belong to the 
mitochondria proteome. Values are relative changes about the control. Orange 
indicates no changes in relative protein quantity. Red indicates a decrease in relative 


















































Figure 3. Complex I activity in human neuroblastoma, SH-SY5Y, treated with mUB at 
1, 5, and 10 micromolar. Complex I activity is significantly decreased by hydrogen 
peroxide treatment. mUB treatment rescued complex I activity from hydrogen 














Figure 4. Percent Fluorescent signal of apoptotic cells after incubation with juglone 
and treatment with mUB, or solvent control. Fluorescent microscopy images of C. 
elegans. Staining using SYTO-12 for apoptotic cells. (A) C. elegans treated with 
Juglone and 0.05% DMSO. (B) C. elegans treated with Juglone and 1µM mUB. (C) C. 
elegans treated with Juglone and 5µM mUB. (D) C. elegans treated with Juglone and 
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Methylated urolithin B identified as a poly-ADP-ribose polymerase-1 inhibitor by 
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The biotransformation of ellagic acid by specific species gut microflora results in the 
production of a group of compounds known as urolithins. The bioactivity of these 
compounds has been studied in the context of multiple indications. One of the most 
studied bioactivities is cancer where several therapeutic mechanisms of urolithins have 
been proposed. However, recent research has identified that urolithins may also have 
neuroprotective effects. As mechanisms responsible for the induction of cancerous cell 
death are not likely to be responsible neuroprotection, we investigated possible 
protein-urolithin interactions in a human neuroblastoma cell model. Using a 
mechanism of action deconvolution method called drug affinity responsive target 
stability (DARTS) we identified that the model compound, methylated urolithin B, 
binds to the protein poly ADP-ribose polymerase-1 (PARP-1) and inhibits its activity 
at nanomolar concentrations. This activity may help to explain the anti-cancer and 
neuroprotective effects of urolithins as PARP -1 inhibitors are currently on the market 
as cancer therapies and have gained attention in the current literature for potential their 




1.0 Introduction  
 
Urolithins are low molecular weight microbiota metabolites that have been studied in 
relation to numerous indications1,2. Of these, the most notable is oncology where 
urolithins have been studied regarding in vitro cancer cell viability3. Several 
publications implicate molecular targets by which urolithins may exert an anti-cancer 
therapeutic benefit4,5. However, recent reports suggest that some urolithins may have 
neuroprotective effects6. Treatment with urolithins has been demonstrated to decrease 
neuroinflammation and attenuate mitochondria dysfunction as induced by 
aging7.While molecular targets of urolithins’ anti-cancer effects have been suggested, 
the same targets are not likely to be responsible for the observed neuroprotective 
effects. Urolithin induced cell-cycle arrest is observed at high concentrations, ~50 µM, 
which is unlikely to be found in the brain. Therefore, we assert that molecular 
mechanisms, distinctly different from those related to cancer, must exist to explain 
urolithin’s neuroprotective properties.  
 
Given this hypothesis, we chose to investigate molecular targets of methylated 
urolithin B (mUB), a model compound, within human neuroblastoma, SH-SY5Y, 
using drug affinity responsive target stability (DARTS). This technique is used for 
identifying small molecules’ molecular targets. DARTS relies on the thermodynamic 
stabilization of protein-ligand complexes and their resistance to protease degradation8. 
After incubating SH-SY5Y cell lysate with mUB and a protease, SDS-PAGE is used 
to determine differences in protein digestion, indicating a complex has formed 
between a protein and mUB. We identified a band of protein protected from protease 





The protein from the band of interest was extracted and eighteen peptides were 
identified from the band (Table 1). Seventeen of these peptides corresponded to 
proteins in the poly ADP-ribose family. Using the protein BLAST software tool 
(NCBI, Bethesda, MD) it was identified that several of these peptides correspond to 
conserved domains within the PARP family (Table 2). Given that PARP-1 is the most 
represented protein in the band of interest, the molecular weight of the band of interest 
most closely matches with PARP-1’s known molecular weight, and several of the 
peptides identified are conserved within the protein family, we tentatively assigned the 
identity of the protein band to be PARP-1. This initial identity from mass spectrometry 
was then confirmed by a western blot (Figure 2). To further validate that PARP-1 is a 
molecular target of mUB, PARP-1 activity was measured in the presence of activated 
DNA, PARP-1’s endogenous target, and varying concentrations of mUB (Figure 3). 
At low concentrations, 100 nM, PARP-1 activity was inhibited about 20% with an 
increasing trend of inhibition with the highest concentration tested, 500 nm, inhibiting 
about 30% of PARP-1 activity.  
 
Further target validation comes from homology structure analysis. A structurally 
similar compound, 6(5H)-phenanthridinone (Figure 4) is a known PARP-1 inhibitor 
with an IC50 of 300 nM9. Despite mUB being a weaker inhibitor than 6(5H)-
phenanthridinone, a significant level of PARP-1 inhibition can be reached with 
concentrations much lower than those commonly tested in in vitro and in vivo models. 
With this in mind, it is important to consider the effect of PARP-1 inhibition when 




urolithins, it is likely that many if not all of the urolithins can modulate PARP-1 
activity. However, this has yet to been established and warrants future investigation. 
 
As many groups have reported several different bioactivities of urolithins that are 
fundamentally different than anti-cancer activity, we investigated alternative 
mechanisms of action which might explain these reports. We found that the model 
compound, mUB, is an inhibitor of PARP-1 which is implicated in several diseases 
including cancer and neurodegenerative disease. These findings help to explain the 




2.0 Experimental  
 
2.1 Synthesis of methylated urolithin B 
A previously published synthesis route was used for the synthesis of mUB10. The 
identity of the compound was verified via high-performance liquid chromatography.   
 
2.2 Cell culture and maintenance  
Human neuroblastomas, SH-SY5Y, were purchased from ATCC (Manassas, VA) and 
cultured using standard laboratory procedures. Cells were differentiated using all-trans 
retinoic acid as previously described.11 Cells were harvested via trypsinization (0.25% 
Trypsin/EDTA, Life Technologies, Grand Island, NY). After trypsinization, cells were 
centrifuged at 1500 rpm for 5 minutes. Cells were then stored on ice until further 
processing.      
 
2.3 Drug affinity responsive target stability  
DARTS was performed as described with modifications12. Briefly, SH-SY5Y cells 
were lysed with M-PER (Thermo Fisher, Waltham, MA) on ice for 10 minutes 
followed by centrifugation (1500 rpm for 5 minutes). The lysate was split into 99 µL 
aliquots in 1.5mL centrifuge tubes. To one centrifuge tube, 1 µL of 50% DMSO was 
added as a solvent control. To a separate centrifuge tube, 1 µL of 1,000 µM 
methylated urolithin B in 50% DMSO was added to a final concentration of 10 µM 
methylated urolithin B. The resulting mixtures were then incubated for thirty minutes 
at room temperature with vigorous shaking. Each tube was split into three separate 
aliquots in 1.5mL centrifuge tubes. To the tubes was added 2 µL of protease in a ratio 




temperature. At that time, 2 µL of 20x protease inhibitor cocktail (Sigma-Aldrich, St. 
Louis, MO) was added along with an equal volume of 2x Laemmli sample buffer 
(Bio-Rad, Hercules, CA) and the samples were boiled for ten minutes. After heating, 
samples were frozen at -80˚C until further processing.     
 
2.4 SDS-PAGE  
Pre-cast polyacrylamide gels (4-20% polyacrylamide gradient with ten 50 µL wells) 
were purchased from Bio-Rad (Hercules, CA). Gels were placed into an 
electrophoresis chamber and immersed in SDS running buffer (25 mM tris, 192 mM 
glycine, 0.1% SDS). Gels were run at 24 mA until the loading buffer dye had reached 
the bottom of the gel. Then, gels were fixed with a solution of 10% acetic acid, 25% 
isopropanol, and 65% de-ionized water for 15 minutes. After fixing, gels were stained 
with Coomassie Blue (10% acetic acid, 0.006% Coomassie Blue dye, 90% de-ionized 
water) for two hours. Gels were then de-stained with 10% acetic acid until the protein 
bands had become visible.  
 
2.5 Protein Identification  
Proteins were extracted from the polyacrylamide gel matrix as previously described 
with modifications13. Briefly, protein bands were excised from SDS-PAGE gels with a 
razor blade and placed into 1.5 mL centrifuge tubes. Bands were de-stained with 10% 
acetic acid, with changes every 30 minutes, until the bands were completely de-
stained. Then, disulfide bonds were reduced and cystine residues were alkylated with 
dithiothreitol (DTT) and iodoacetamide (IAA) respectively. Gel bands were 




removed and the bands were lyophilized overnight. Then, gel bands were re-hydrated 
on ice for 1 hour with a 10 µg/mL solution of trypsin in 25 mM ammonium 
bicarbonate. Next, the excess solution was removed and the gel piece was covered 
with 25 mM ammonium bicarbonate. The protein band/trypsin mixture was then 
incubated overnight at 37°C. After incubation, the supernatant was collected and 
placed into a 1.5 mL centrifuge tube. The gel band was washed with 20% acetonitrile, 
1% trifluoroacetic acid, and 79% H2O for 1 hour while vortexing. The supernatant was 
removed and added to the previous step’s supernatant. The combined fractions were 
frozen at -80°C overnight and then lyophilized to dryness. Samples were reconstituted 
in 50% acetonitrile/ 50% water and placed into HPLC sample vials until further 
processing. The protein identity was determined using peptide mass fingerprinting 
with a SciexTripleTOF 5600 mass spectrometer (Framingham, MA) using previously 
described methods14.       
 
2.6 Protein BLAST  
Peptide sequences corresponding to the PARP protein family were analyzed via the 
protein BLAST tool freely available from the NCBI (Bethesda, MD) 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). FASTA peptides sequences were queried for 
Homo sapiens proteins in the SwissProt database. The protein-protein algorithm was 








SDS-PAGE gels of cell lysate processed via the DARTS method were prepared as 
described following standard laboratory procedures.  Cell lysates were treated with 
pronase at pronase:protein ratios of 1:1000, 1:500, and 1:100. Proteins were 
transferred to a nitrocellulose membrane using a mini Trans-Blot transfer apparatus 
(Bio-rad, Hercules, CA) at 100mA for 16 hours at 4°C. Membranes were removed 
from the apparatus and blocked in 5% bovine serum albumin (BSA) for 1 hour at 
room temperature. Then PARP-1 antibody (Abcam, Berlin, Germany), diluted in 
blocking buffer, was applied to the membrane and allowed to incubate for 16 hours at 
4°C. After several washes in TBST (137 mM NaCl, 2.7 mM KCl, 19 mM Tris Base), 
primary antibody detection was carried out using a Vectastain Elite ABC kit (Vector 
Labs, Burlingame, CA) as per the manufacturer’s instructions.      
 
2.8 PARP-1 Inhibition 
The inhibitory effect of mUB on PARP-1 activity determined with a PARP 
homogenous inhibition assay kit (Trevigen, Gaitherburg, MD) as per the 
manufacturer’s instructions. All tested mUb concentrations were performed in 
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Figure 1. SDS-PAGE gel of SH-SY5Y cell lysate processed with the DARTS method 
and stained with Coomassie Blue. Asterisks flank bands protected from digestion 















Table 2. List of conserved protein regions for the 17 peptides identified as belonging 
to the PARP family.   
 
Name  Accession   Description  E-value  
PLN03124 PLN03124 PARP; Provisional 7.77E-12 
PARP_Like cd01437 PARP Catalytic Domain 1.03E-11 
PARP pfam00644 PARP Catalytic Domain 7.68E-10 
zf-PARP pfam00645 PARP Zinc Finger Region 2.70E-04 












Figure 2. Western blot confirming that the identity of the protected protein band to be 
PARP-1. The “-” indicates that pronase or mUB was not added to the reaction 
mixture. The “+” indicates the addition of pronase or mUB to the reaction mixture. A 
box surrounds the two bands which demonstrate that the addition of mUB protects 
PARP-1 from pronase digestion. “+” = 1:1000, “++” = 1:500, “+++” = 1:100 








































 CHAPTER 3 
 
EFFICACY OF A PHENOLIC-ENRICHED EXTRACT OF MAPLE SYRUP IN A 
MOUSE MODEL OF ALZHEIMER’S DISEASE 
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In recent years, the role of inflammation in Alzheimer’s Disease pathogenesis and 
progression has come to the forefront in the field. Several studies have suggested that 
chronic inflammation, as a result of Alzheimer’s Disease pathology, can lead to 
exacerbated disease progression. Therefore, targeting inflammation is a likely 
therapeutic option. The sugar free, phenolic-enriched extract of maple syrup, known as 
MSX, is a mixture of polyphenols and has been studied for safety, tolerability, and a 
variety of different biological effects. Of these, MSX has shown to reduce 
neuroinflammation in the human neuroblastoma cell line, SH-SY5Y. For these 
reasons, this study investigated the efficacy of MSX in a transgenic mouse model of 
Alzheimer’s disease and examine neuroinflammation as outcomes measure to 
determine efficacy. We found that two doses of MSX were able to significantly 
decrease the expression of several proteins related to inflammatory cascades and 
phenotypic markers of innate immune cells that are thought to specifically respond to 
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Alzheimer’s disease (AD) is a growing global health crisis exacerbated by increasing 
life span and an aging demographic. Convergent lines of evidence, including genome-
wide association studies, strongly implicate neuroinflammation in the pathogenesis of 
AD. Several dietary agents, including (poly)phenolic-rich foods, show promise for the 
prevention and/or management of AD, which in large part, has been attributed to their 
anti-inflammatory effects.  We previously reported that a food-grade phenolic-
enriched maple syrup extract (MSX) inhibit neuroinflammation in vitro but whether 
these effects were translatable in vivo remain unknown. Here, we report that oral 
administration of MSX (at doses of 100 and 200 mg/kg for 30 days) attenuates several 
neuroinflammatory markers in 3xTg-AD mice, a murine model of amyloid and tau 
pathology occurring in AD. Proteomics analysis by LC-MS/MS with SWATH 
acquisition showed that 3xTg-AD mice dosed orally with MSX have decreased 
expression of several inflammatory proteins, including, most notably, the AD risk-
associated protein “triggering receptor expressed on myeloid cells-2” (TREM2), as 
well as stimulator of interferon genes TMEM173, and suppressor of cytokine 
signaling-6 (SOCS6). These data demonstrate that oral administration of this maple 
syrup derived natural product reduces key neuroinflammatory indices of AD in the 
3xTg-AD model of amyloid and tau pathology. Therefore, further studies to 
investigate MSX’s potential as a dietary intervention strategy for AD prevention 





1.0 Introduction  
The immune system is integral to the central nervous system (CNS). Having a major 
role in brain homeostasis and brain development, the immune system, particularly 
innate immunity, is necessary for proper brain function over an individual’s lifetime. 
Under homeostatic conditions, many cell types with several different phenotypes work 
in concert to survey the brain and regulate inflammatory responses. However, it is 
thought that chronic diseases affecting the CNS dysregulate the immune system 
function, which may in turn lead to exacerbated pathology1,2. For this reason, 
inflammation has become an important target for neurodegenerative disease drug 
discovery research.     
 
Alzheimer’s disease (AD) is a chronic, neurodegenerative disease with a well-
established connection to the inflammatory response3. The hallmark pathological 
lesions in AD, amyloid-b plaques and neurofibrillary tangles, are associated with 
dysregulation of central immune system function4. Recently, several groups have 
reported that AD pathology involves a phenotypic switch of innate immune cells from 
a homeostatic state to a neurodegenerative state5,6. Interestingly, after switching to a 
neurodegenerative disease state, these cells lose their ability to regulate brain 
homeostasis, a possible mechanism for how dysregulation of the innate immune 
system can exacerbate pathology6. Studies investigating a potential molecular switch 
for the shift between “homeostatic” and “neurodegenerative” phenotypes have 
identified a signaling pathway that includes the proteins triggering receptor expressed 
on myeloid cells-2 (TREM2) and apolipoprotein E (APOE) as key participants6. By 




phenotype could be restored. These findings suggest that suppressing 
neuroinflammation and the TREM2-APOE pathway may have a beneficial therapeutic 
effect against AD. 
 
Evidence from genome-wide association studies (GWAS) has implicated variants in 
the APOE and TREM2 genes with risk for AD. While the association between APOE 
and AD has been established since the early 1990’s, variants of TREM2 and AD risk 
have recently emerged. A clear genetic relationship exists between TREM2 and AD, 
but the biological mechanism by which an increase in risk or protective effect occurs 
is still unknown. With regard to other types of dementia, mutations in TREM2 leading 
to its complete loss of function result in Nasu-Hakola disease (NHD), a rare disorder 
leading to presenile dementia. There are many similarities between the brains of 
patients with AD and NHD such as astrogliosis and immune cells in pro-inflammatory 
states7. Furthermore, patients with NHD can develop AD-like pathology with 
amyloid-b plaques and neurofibrillary tangles8. These findings demonstrate an 
important connection between TREM2 induced dysregulation of the immune system 
and the effects this can have on the brain.  
 
Several attempts have been made to treat AD by regulating inflammation. For 
instance, the non-steroidal anti-inflammatory drugs (NSAIDs), celexoxib and 
naproxen, were evaluated for their effects on improving cognitive performance in 
humans with AD. However, no statistically significant effects were observed with 
NSAID treatment9. While GWASs have clearly identified the immune system as a 




fully understood. This lack of mechanistic understanding of AD has made drug 
discovery efforts difficult.  A potential method to circumvent this hurdle is to utilize 
medicinal plant foods and their derived products, especially those rich in 
(poly)phenolics which are known for their anti-inflammatory properties, as dietary 
intervention strategies for AD prevention and/or management.  In fact, several 
phenolic-rich natural products including certain fruits, berries, spices, and green tea 
have been reported to have beneficial effects against AD10–12. Recently,  it has been 
reported that polyphenol dietary supplements  can improve deficits in cognition and 
decrease arachidonic acid levels in the mouse model of AD, 3xTg-AD13–15.  
 
Our group has conducted extensive chemical compositional studies on maple syrup, a 
natural sweetener produced by boiling the sap of sugar maple (Acer saccharum) trees, 
leading to the identification of over 60 phenolic constituents16–18. A phenolic-enriched 
maple syrup extract was reported to decrease oligomerization and aggregation of both 
Aβ1-42 and tau peptides19  In addition, our group reported on the anti-
neuroinflammatory effects and anti-AD effects of a phenolic-enriched maple syrup 
extract (MSX) in vitro and in Caenorhabditis elegans 20.   However, to date, the 
effects of MSX against AD has not been studied in any rodent models.  Here we 
sought to investigate whether MSX exerts anti-inflammatory effects using the 3xTg-
AD mouse model of AD.      
 
 
GWAS and mRNA screening techniques have led to a deeper understanding of the 




limited interpretation as genetic variants and mRNA do not perfectly correlate with 
protein expression. As the functional component, monitoring protein expression is 
preferred but often impractical. Here, we utilized sequential window acquisition of all 
theoretical mass spectra (SWATH-MS), a data-independent proteomics method which 
greatly improves upon the sensitivity and reproducibility of more traditional proteomic 
approaches. SWATH-MS allows for the efficient and comprehensive characterization 






2.1 Production of MSX 
Details of the preparation and chemical standardization of a food grade phenolic-
enriched maple syrup extract (MSX) has been previously reported17. MSX contains 
over 60 phenolic constituents present in the whole maple syrup food but with reduced 
sucrose content. The extract is well tolerated with no toxicity observed at 1000 mg/kg 
for 7 days in Sprague-Dawley rats17. 
 
2.2 Mice 
All female 4-week-old transgenic 3xTg-AD mice (The Jackson Laboratory, Bar 
Harbor, ME) were used for all experiments. These mice harbor three familial 
mutations of AD: (1) amyloid precursor protein (APP) KM670/671NL (Swedish). (2) 
Microtubule associated protein tau (MAPT) P301L. (3) Presenillin-1 M146V. These 
particular mice were chosen because they display intra-neuronal amyloid deposits 
early in age, similar to the early stages of AD.  
 
Mice were maintained in the University of Rhode Island’s mouse vivarium with a 12-
hour light/dark cycle with free access to food and water. Prior to treatment, mice were 
acclimated for one week. Following acclimation, mice were treated for thirty days 
with 100 mg/kg/day or 200 mg/kg/day MSX, or an equal volume of 0.5% 
carboxymethylcellulose (CMC) as a solvent control via oral gavage five times per 
week. Allometric scaling was used to choose doses of MSX which translate to a 
reasonable dose in a human21. Based on this scaling method, the low and high doses 




treatment groups consisted of six mice. One mouse in the 100 mg/kg/day MSX group 
had to be euthanized per order of the attending veterinary due to hydrocephalus.  An 
additional five female C57BL/6 mouse brains, of the same age, were purchased from 
BioIVT (Westbury, NY) to act as genetic background expression controls.  
 
After thirty days of treatment, mice were anesthetized using an isoflurane chamber 
(Patterson Scientific, Waukesha, WI). Mice were then euthanized via decapitation and 
their brains removed and immediately stored on ice. Following removal, brains were 
snap frozen in liquid nitrogen. After freezing, brains were stored at -80°C until further 
processing. All protocols and procedures were approved by the University of Rhode 
Island’s Institutional Animal Care and Use Committee.  
 
2.3 Quantification of amyloid species  
Sections of cortex or hippocampus were weighed out and placed into 2 mL screw cap 
vials containing 1.4 mm ceramic beads (Omni International, Kennesaw, GA). Eight 
volumes of 5 M guanidine-HCl in 50 mM Tris (pH 8.0) was added to the brain 
sections. Brains were homogenized in a Bead Ruptor 24 (Omni International, 
Kennesaw, GA). After which time the homogenate was shaken at room temperature 
for three hours. Before amyloid analysis, the homogenate was diluted 10-fold with 
PBS containing 1x protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO). 
Quantification of amyloid was performed using an Amyloid beta 42 Mouse ELISA Kit 
and Amyloid beta 40 Mouse Kit (ThermoFisher, Waltham, MA) following the 
manufacturer’s instructions. Absorbance was read using a SpectraMax microplate 





2.4 Lipid Peroxidation Analysis 
Brain lipid peroxidation was analyzed using a fluorometric lipid peroxidation (MDA) 
assay kit (Abcam, Cambridge, UK). Brains sections from cortex and hippocampus 
were weighed and homogenized in 150 µL of water and three µL BHT (supplied in the 
kit). Samples were prepared in 2 mL screw cap vials containing 1.4 mm ceramic beads 
and homogenized with a Bead Ruptor 24 (Omni International). Proteins were 
precipitated with 153 µL of 2 N perchloric acid. The quantification of lipid 
peroxidation from this prepared homogenate was performed following the 
manufacturer’s instructions. Fluorescence was read using a SpectraMax microplate 
reader (Molecular Devices, San Jose, CA).  
 
2.5 Brain Tissue Preparation and Protein Digestion  
Pre-weighed brain tissue was transferred to 2 mL screw cap vials filled with 1.4 mm 
ceramic beads. Vials contained 7 volumes of pre-chilled homogenization buffer (50 
mM Tris-HCl (pH 7.4), 0.5 mM EDTA, 0.25 M sucrose, and 20 µM BHT). Brain 
tissue was then homogenized using a Bead Ruptor 24 (Omni International, Kennesaw, 
GA). The resulting homogenate was centrifuged at 10,000 x g for 20 minutes at 4˚C. 
Homogenate protein concentration was determined using a Pierce BCA protein kit 
(ThermoFisher, Waltham, MA). Homogenate was diluted to 2.5 mg/mL using 50 mM 
ammonium bicarbonate. Proper dilution was confirmed using a NanoDrop One/OneC 
microvolume 9UV-Vis spectrophotometer to conserve sample (ThermoFisher, 




trypsin (SCIEX, Framingham, MA) along with pressure cycling technology (PCT) as 
previously reported22.    
 
2.6 Mass Spectrometry Data Acquisition with SWATH-MS 
Mass spectrometry was performed as previously described with modifications22. Data 
was acquired on a SCIEX TripleTOF® 5600 mass spectrometer using a DuoSpray™ 
ion source (SCIEX, Framingham, MA) coupled to an Acquity HClass UHPLC system 
(Waters Corp., Milford, MA).  An Acquity VanGuard pre-column (2.1 x 5 mm2, 300 
Å, 1.7 µm) with an Acquity UPLC Peptide BEH C18 column (2.1 x 150 mm2, 300 Å, 
1.7 µm) was used to achieve separation.  The column temperature was set to 40˚C and 
the autosampler was set to 10˚C.  A linear gradient was used with a flow rate of 100 
µL/min for 90 min. Mobile phase A consisted of 98% acetonitrile, 2% water and 0.1% 
formic acid.  Mobile phase B consisted of 98% water, 2% acetonitrile and 0.1% formic 
acid.  The gradient was as follows: 98% A from 0 to 5 min, 98% to 75% from 5 to 55 
min, 75% to 50% A from 55 to 60 min, 50% to 20% from 60 to 70 min.  Mobile phase 
A was held at 20% from 70 to 75 min and returned to 98% A at 80 min.  The column 
was held at 98% A for 10 min to equilibrate prior to the next sample.  A mixture of 
trypsin-digested β-galactosidase peptides were used between every 10 samples to 
calibrate masses and monitor the QTOF detector. 
 
Positive ionization mode was used for SWATH data acquisition. The mass 
spectrometer parameters are as follows: gas 1 60 psi, gas 2 60 psi, curtain gas 25 psi, 
temperature 450˚C, ion spray voltage floating 5500 V, declustering potential 120, 
collision energy 10 and collision energy spread 5. For data acquisition, a maximum of 




from 2 to 4.  A range of m/z 300-1500 was used for exclusion criteria and all ions that 
had an intensity greater than 25 cps were chosen for MS/MS analysis. The temperature 
was set at 400˚C and the total cycle time was 3.95 sec.  Seventy SWATH windows per 
cycle were collected over m/z 400-1100 with each window size being m/z 10. 
 
2.7 Mass Spectrometry Data Analysis  
SWATH data was used for peptide and transition selections in Skyline (MacCoss lab, 
University of Washington). The FASTA file for each protein to be analyzed (Table 1) 
was imported into Skyline. Three surrogate, flyable peptides containing at least 3 
transitions were selected and correlated with the other chosen peptides for each 
respective protein. Peptide cutoff criteria included a minimum length of 6 and 
maximum length of 25 amino acids and did not occur in the transmembrane domain, 
did not contain posttranslational modifications or polymorphic variations.  Peptide 
selections were filtered down to two peptides per protein wherever possible. The 
program MPPreport was used to calculate the total area under the curve for each 
protein analyzed. Subsequently, transgenic animal protein expression was normalized 
to wild-type animal protein expression.  
 
2.8 Statistics  
The statistical program Prism 7 (Graph Pad, San Diego, CA) was used for statistical 
analysis and generation of figures. Comparing wild-type and untreated 3x-Tg-AD 
protein expression was done with multiple, two-tailed t-tests with a a level of 0.05. 
Two-way ANOVAs and Dunnett’s post hoc test were used to compare protein 






3.1 Early stage AD pathology induces changes in the expression of inflammatory 
proteins in the brains of 3xTg-AD mice. 
 
To better understand the nature of the inflammatory response at this stage of 
pathology, the expression of inflammatory and AD-related proteins (Table 1) were 
analyzed by SWATH-MS. Several inflammatory mediators were differentially 
expressed in the cortex of 3xTg-AD mice as compared to wild-type mice (Table 2). 
However, only two proteins were differentially expressed in the hippocampus (Table 
3). These alterations in protein expression of inflammatory mediators and AD-related 
proteins were then used as outcome measure for the possible efficacious benefit of 
MSX supplementation.  
 
3.2 Oral supplementation of MSX does not alter the generation of amyloid 
species or the abundance of lipid peroxides 
 
In addition to the expression of inflammatory mediators, lipid peroxidation and 
pathogenic generation of amyloid species were evaluated as outcome measures to 
quantify the potential efficacious benefits of MSX. No statistically significant 
differences in lipid peroxidation levels were found between the cortex of untreated or 
treated animals (untreated vs. low dose p=0.9998, untreated vs. high dose p=0.9993). 
The same trend was identified in the hippocampus (untreated vs. low dose p=0.9821, 
untreated vs. high dose p=0.2245) (Figure 1). The generation of Ab42 in the cortex was 
not found to be statistically significant across groups (untreated vs. low dose 
p=0.9999, untreated vs. high dose p=0.9978). Generation of Ab42 in the hippocampus 
was slightly lower than the cortex, but generation did not change across treatment 
groups (untreated vs. low dose p=0.1259, untreated vs. high dose p=0.1350) (Figure 




untreated vs. low dose p=0.9065, untreated vs. high dose p=0.9978) (Hippocampus: 
untreated vs. low dose p=0.9995, untreated vs. high dose p=0.9942).        
 
3.3 Oral MSX supplementation significantly reduces the expression of several 
pro-inflammatory proteins correlated with AD in the cortex of 3xTg-AD mice 
 
With MSX supplementations, several proteins related to AD were downregulated to 
near wild-type expression levels (Figure 4). TREM2 (p=<0.0001), CD36 (p=0.0017), 
ITGAX (p=<0.0001), and CSF1R (p=0.0005) were overexpressed in transgenic 
animals compared to wild-type, and high dose (200 mg/kg/day) MSX reduced 
expression to near baseline expression. Low dose (100 mg/kg/day) of MSX has a 
similar trend to the high dose, with TREM2 (p=<0.0001) and CSF1R (p=0.0264) 
showing reduced expression. In both the high and low dose groups, APOE expression 
was unchanged (p=0.3798, p=0.3798 respectively).  
 
The inflammatory mediators TMEM173 and SOCS6 were highly overexpressed in the 
control treated 3xTg-AD mice compared to wild-type expression. Both the high and 
low dose MSX treatments reduced TMEM173 (p=<0.0001, p=0.0036 respectively) 
and SOCS6 (p=<0.0001, p=<0.001 respectively) expression to near baseline 
expression (Figure 5). 
 
The higher dose of MSX reduced the expression of proteins associated with AD and 
inflammation associated innate immune cells. The expression of C1qa, while 
unaffected by low dose MSX (p=0.2996) was significantly reduced by high dose MSX 




(p=<0.0001) were also downregulated toward baseline expression with high dose 
MSX treatment (Figure 6).  
 
Several inflammatory mediators and AD related proteins analyzed were not shown to 
have differential expression with either high or low MSX treatment. However, TNFA 
(p=0.0007), SOD1 (p=0.0378), TLR4 (p=0.0217), and were upregulated with low dose 
MSX treatment but not with high dose MSX treatment (p=0.0694, p=0.5334, 
p=0.8886, p=0.9959 respectively) (Figure 7). High dose MSX reduced TIMP2 
(p=0.0484) expression but these differences were not seen in low dose MSX 
treatment. BACE expression was increased in both the high (p=<0.0001) and low 
(p=0.0044) MSX groups.      
 
3.4 Oral supplementation of MSX does not significantly alter the expression of 
pro-inflammatory proteins in the hippocampus of 3xTg-AD mice 
 
The hippocampus had minimal changes in protein expression across all of the proteins 
analyzed (Table 4). However, SOCS6 was marginally overexpressed in wild-type 
mice and high dose of MSX reduced its expression to below baseline expression 
(p=0.0424). High dose MSX also reduced TIMP2 (p=0.0006) and FADD (p=0.0255) 
expression in the hippocampus, but low dose MSX did not affect the expression of any 
of these proteins (Figures 8-11).    






4.0 Discussion  
There is a clear relationship between neuroinflammation and AD23–27. Evidence from 
genome-wide association studies (GWAS), genome-wide expression studies (GWES), 
and immunohistochemistry (IHC) on human AD tissue suggest that the immune 
system is dysregulated in patients with AD28–32. Furthermore, dysregulation of the 
innate immune system may be contributing to the pathology or progression of AD33,34. 
Therefore, we sought to characterize the inflammatory response of the 3xTg-AD 
mouse model using the proteomics technique SWATH-MS. Then, we evaluated the 
effects of a phenolic-enriched extract of maple syrup, MSX, on the model’s specific 
inflammatory response.  
 
Dietary sources of anti-inflammatory compounds which may alter neuroinflammation 
are plant polyphenols. Several phenolic-enriched plant extracts and isolated pure 
compounds o have been studied in the context of inflammation and AD35–38. However, 
in vitro research often induces inflammation with LPS, a ligand of toll-like receptor-4 
(TLR4). While LPS produces robust and repeatable results, recent studies 
investigating the immune response to AD pathology have demonstrated the 
complexity and uniqueness of this response5. MSX has shown anti-inflammatory and 
neuroprotective properties in vitro with LPS stimulation19. Therefore, we sought out to 
evaluate these effects in an in vivo model of AD.  
 
Early in pathology, the 3xTg-AD has several changes in the expression of 
inflammatory mediators. At this stage of pathology, the cortex is the most affected 




a custom-made list of inflammatory mediators (Table 1) that have been implicated in 
AD pathology and related inflammatory responses. The largest differences were seen 
with TREM2, TMEM173, and SOCS6. Alterations in the expression of CSF1R, 
ITGAX, and CD36 were also observed which was expected as these proteins have 
been previously implicated in the AD immune response. Surprisingly, APOE was not 
upregulated by pathology. Previous research suggests that APOE works in concert 
with TREM2 to regulate innate immune cell phenotype fate, however we did not 
replicate these findings. As expected, increases in pro-inflammatory proteins were also 
observed. The complement protein C1qA, NOS2, MAPK8, LPL, and the cathepsins 
CTSB and CTSL were all upregulated by 3xTg-AD pathology (Table 2, 3). These 
changes in inflammatory mediators clearly establish that the 3xTg-AD model, even at 
this early stage of pathology, has a significant inflammatory response in the brain.  
 
While there were several significant changes to inflammatory mediators, alteration to 
lipid peroxidation levels were not observed (Figure 1). Often used as a marker of cell 
damage, lipid peroxidation levels correlate with pathology and age39,40. In these 
relatively young animals, differences in lipid peroxidation may be too small to notice 
significant differences. However, as expected with this model, Ab42 generation was 
significantly higher than Ab40. Treatment with MSX did not alter generation of either 
of these amyloid species (Figure 2,3). This suggests that any anti-inflammatory effects 
of MSX are not due to differences in pathological generation of amyloid species. 
 
Once the inflammatory response in the 3xTg-AD model was established with 




inflammatory response as outcome measures. The anti-inflammatory effects of MSX 
were shown to be specific to the cortex. Given the age of the animals used and that in 
this animal model, pathology begins in the cortex and appears in the hippocampus 
later in life, therefore we expected minimal changes to hippocampal protein 
expression41. After MSX treatment, the expression of several proteins that have been 
implicated in AD pathogenesis were reduced (Figure 4). Particularly, CSF1R, a 
promotor of microglia proliferation, was reduced to near basal expression. CSF1R 
serves as an interesting topic as pharmacological inhibition of CSF1R has been shown 
to reduce AD-like pathology in vivo42. Furthermore, the expression of CD36 was also 
significantly reduced. CD36 has been identified as a risk factor for the development of 
AD and has been demonstrated to associate with amyloid plaques and stimulate the 
release of pro-inflammatory cytokines43,44. Similarly, the expression of ITGAX and 
TREM2, markers of innate immune cells in a pro-inflammatory phenotype, were 
reduced5,45. Together, these findings suggest that the phenotype of innate immune cells 
in the brain has changed with MSX treatment. Given that these markers are associated 
with a pro-inflammatory response, it is likely that the immune cell phenotype induced 
by MSX treatment is associated with a reduction in inflammation. Interestingly, the 
expression of APOE was unaltered by MSX treatment. Given previous findings that 
suggest APOE and TREM2 work in concert to alter inflammatory phenotypes, this 
result was unexpected. However, the animals used in this study are relatively young 
and of a different genotype than previously researched models. Our data suggests that 
at the endpoint of this study, APOE expression is not drastically overexpressed. It may 
be possible that the pathology present in the 3xTg-AD mice at the endpoint of this 




pharmacological modulation. Future research that analyses a longer time course of 
MSX treatment and AD pathology progression is necessary.       
 
The expression of two inflammatory mediators, TMEM173 and SOCS6, were 
profoundly increased in control treated animals as compared to wild-type animals 
(Figure 5). MSX treatment was able to reduce the expression of these proteins to near 
baseline levels. TMEM173, also known as the stimulator of interferon genes, is a 
potent initiator of an inflammatory response46. TMEM173 signaling leads to the 
expression of type I interferons which further orchestrates an inflammatory response47. 
Genetic knockouts of TMEM173 in models of murine prion disease reduced the 
expression of inflammatory markers in the brain. While knockouts of type I interferon 
slowed disease progression suggesting that limiting this signaling pathway may be 
beneficial to attenuate neurodegenerative processes48. SOCS6 is a negative regulator 
of receptor tyrosine kinase signaling that is overexpressed in the brains of patients 
with AD49. Expression of SOCS6 can lead to mitochondrial dysfunction and apoptosis 
through the BAX pathway50,51. Mitochondrial dysfunction is thought to play a role in 
AD pathogenesis and/or progression52,53 . Taken together, the profound increase in 
TMEM173 and SOCS6 in 3xTg-AD mice as compared to wild-type mice, and then the 
dose dependent reduction in expression with MSX treatment suggest that MSX alters 
inflammatory signaling. This provides further support that MSX alters the 
inflammatory phenotype of innate immune cells in the brains in 3xTg-AD mice.  
 
Recent work has suggested that a pro-inflammatory phenotype exist in the brains of 




phenotype may also confer a protective or therapeutic benefit to AD pathology. The 
expression of several markers of these cells were significantly increased in the 3xTg-
AD mice which were then decreased by MSX treatment (Figure 6). In particular, 
several cathepsins (CTSB, CTSL), C1qA, and LPL were shown to increase in 
response to 3xTg-AD pathology. MSX treatment significantly reduced the expression 
of these markers. These findings further provide evidence that MSX treatment shifts 
the innate immune cell phenotype away from a pro-inflammatory state. 
 
A select few inflammatory markers were upregulated with MSX treatment. The 
expression of TNF-a and TLR4 was increased with low-dose MSX treatment but not 
with high-dose MSX. In vitro experiments in murine microglia suggest that MSX 
treatment reduces TNF-a  levels, however our results do not replicate these finding20. 
In addition to increases in TNF-a, the cell surface receptor, TLR4, was also increased. 
This finding is not unexpected as TLR4 and TNF-a are part of the same signaling 
pathway. TLR4 has been demonstrated to help coordinate an inflammatory response 
against amyloid pathology54. It is possible that MSX may not act on pathways leading 
to TLR4 expression resulting in increased TLR4 and through its signaling, increases in 
TNF-a expression. Another unexpected result was a modest increase in BACE1 
expression. BACE1 is a secretase responsible for the production of C99, the precursor 
to beta-amyloid. However, this increase did not result in an increase in amyloid 
generation of any species. More research is required to determine if this increase has 





Understanding the mechanism of MSX’s anti-inflammatory effects is complex. As an 
extract, MSX contains several compounds, more than sixty of which have been 
identified by our laboratory16–18, 55-57. The majority of compounds are lignans which 
can act as phytoestrogens and may play a role in estrogen receptor signaling58,59. 
Several other classes of polyphenols are also present which may contribute to the 
reduction in inflammation through sequestration of radical oxygen species60. Our lab 
group has isolated sufficient quantities of more than twenty of the compounds found in 
MSX. When used in a C. elegans model of oxidative stress, only a few of the isolated 
compounds were able to protect the worms from oxidative stress16. This suggests that 
not all compounds found in MSX are active and that a synergy may exist between 
several compounds which leads to the observed effects in this study. The use of bio-
assay guided fractionation or cheminformatics may be useful to better understand the 
chemical constituents of MSX that leads to the reduction of AD neuroinflammation in 
vivo. This topic is under current investigation by our group.    






The immune system has gained recent attention in the neurodegenerative research 
field. Particularly in AD as several clinical trials with therapies aimed at the amyloid 
hypothesis have failed to reach their clinical endpoints. The chronic inflammation as 
seen in the human condition and recapitulated by animal models is thought to enhance 
disease progression and may even be part of AD pathogenesis. Therefore, identifying 
pharmaceutical agents that limit inflammation in the brain though practical routes, 
such as oral administration, is of great importance and may lead to future clinical 
trials. Herein, we have described an orally dosed extract of maple syrup (MSX) that 
reduces neuroinflammation in the early stages of pathology in the 3xTg-AD model of 
AD. By using advanced proteomic techniques, we monitored several proteins to 
characterize the inflammatory phenotype in the brains of wild-type, untreated 
transgenic, and treated transgenic mice with two different doses of MSX. Our results 
demonstrate that MSX treatment may shift the innate immune system’s phenotype 
away from an inflammatory state, potentially to a homeostatic state. However, more 
research is required to rigorously phenotype these cells and how this change may 
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Protein Abbreviation Protein Name
CHIT1 Chitotriosidase-1
CH3L1 Chirinase-2-like protein 1
CCL2 C-C motif chemokine 2
CD14 Monocyte differentiation antigen CD14
ITGAM Integrin alpha-M
TNFA Tumer Necrosis Factor-alpha
IL1B Interleukin-1 beta
IL15 Interleukin-15
TNF10 Tumer necrosis factor ligand superfamily member 10
CD36 Platelet glycoprotein 4
BACE1 Beta-secretase 1
TNR11 Tumer necrosis factor receptor superfamily member 11a
TLR4 Toll-like receptor 4
CD47 Leukocyte surface antigen CD47
NLRP3 NACHT, LRR and PYD domains-containing protein 3
IRAK4 Interleukin-1 receptor accociated kinase 4
NOS2 Nitric oxide synthase, inducible
SOD1 Superoxide dismutase [Cu-Zn]
TMEM173 Stimulator of interferon genes protein
FADD FAS-associated death domain protein 
SHARPIN Sharpin
SOCS6 Supressor of cytokine signaling 6
APP Amyloid precursor protein 
P2RY12 P2Y purinoceptor 12
APOE Apolipoprotein E
TCF4 Transcription factor 4
TREM2 Triggering receptor expressed on myeloid cells 2
CST3 Cystatin-C
CSF1R Macrophage colony-stimulating factor 1 receptor
C1QA Complememnt C1q subunit A
TMEM119 Transmembrane protein 119
CTSB Cathepsin B




CSF1 Macrophage colony-stimulating factor 1 
LIRB4 Leukocyte immunoglobulin-like receptor subfamily B member 4





Table 2. Comparison of protein expression between wildtype mice and 3xTg-AD mice 
in the cortex. Individual t-tests were used to determine statically significant 




Protein Abbreviation t  ratio Statistically Significant Adjusted P-Value
CHIT1 2.805 No 0.2767
CH3L1 3.01 No 0.2229
CCL2 2.82 No 0.2767
CD14 1.618 No 0.7013
ITAM 5.821 Yes 0.0088
TNFA 4.604 Yes 0.0316
IL1B 4.046 No 0.0647
IL15 1.604 No 0.7013
TNF10 2.164 No 0.4861
CD36 5.572 Yes 0.0102
BACE1 3.477 No 0.1245
TNR11 1.25 No 0.7013
TLR4 1.862 No 0.5948
CD47 2.753 No 0.2767
NLRP3 2.772 No 0.2767
IRAK4 5.336 Yes 0.0131
NOS2 5.585 Yes 0.0102
SOD1 1.402 No 0.7013
TMEM173 5.638 Yes 0.0101
FADD 3.094 No 0.2077
SHARPIN 1.975 No 0.5642
SOCS6 7.479 Yes 0.0015
APP 3.548 No 0.1177
P2RY12 4.209 No 0.0532
APOE 1.258 No 0.7013
TCF4 2.437 No 0.3683
TREM2 8.696 Yes 0.0005
CST3 1.205 No 0.7013
CSF1R 8.209 Yes 0.0007
C1QA 4.697 Yes 0.0288
TMEM119 1.435 No 0.7013
CTSB 7.463 Yes 0.0015
UFO 6.644 Yes 0.0035
CTS7 5.636 Yes 0.0101
CTSL 7.261 Yes 0.0018
LPL 3.661 No 0.1042
CSF1 4.752 Yes 0.0277
LIRB4 1.592 No 0.7013
TIMP2 6.283 Yes 0.0052




Table 3. Comparison of protein expression between wildtype mice and 3xTg-AD mice 
in the hippocampus. Individual t-tests were used to determine statically significant 
differences in protein expression between groups.  
 
 
Protein Abbreviation t  ratio Statistically Significant Adjusted P-Value
CHIT1 2.699 No 0.5356
CH3L1 1.221 No 0.9769
CCL2 2.411 No 0.6737
CD14 1.373 No 0.9734
ITAM 3.725 No 0.1571
TNFA 3.527 No 0.2026
IL1B 3.489 No 0.2081
IL15 0.01164 No 0.9986
TNF10 0.8633 No 0.9906
CD36 1.904 No 0.8841
BACE1 7.581 Yes 0.0014
TNR11 1.225 No 0.9769
TLR4 1.416 No 0.9724
CD47 5.23 Yes 0.0220
NLRP3 1.464 No 0.9701
IRAK4 0.3198 No 0.9974
NOS2 1.078 No 0.9769
SOD1 3.796 No 0.1456
TMEM173 1.557 No 0.9646
FADD 0.2949 No 0.9974
SHARPIN 2.097 No 0.8156
SOCS6 2.26 No 0.7379
APP 2.538 No 0.5956
P2RY12 0.8742 No 0.9842
APOE 1.928 No 0.8732
TCF4 3.888 No 0.1309
TREM2 0.04763 No 0.9986
CST3 2.798 No 0.4782
CSF1R 1.306 No 0.9690
C1QA 2.09 No 0.8156
TMEM119 4.004 No 0.1138
CTSB 0.8642 No 0.9842
UFO 1.871 No 0.8745
CTS7 1.547 No 0.9582
CTSL 1.319 No 0.9690
LPL 2.642 No 0.5455
CSF1 3.813 No 0.1421
LIRB4 0.6078 No 0.9842
TIMP2 1.141 No 0.9691




Figure 1. Abundance of lipid peroxidation is unaltered in the brains of 3xTg-AD mice 





























Figure 4. Differential expression of AD related proteins in the cortex of 3xTg-AD 
mice with MSX treatment. The dietary supplementation of MSX results in a dose-
dependent decrease in the expression of inflammatory mediators specifically 
implicated in AD. Data shown as mean of all biological replicates with standard 













Figure 5. Proteins highly overexpressed in untreated 3xTg-AD mice were significantly 
reduced in the cortex of 3xTg-AD mice with MSX treatment. The dietary 
supplementation of MSX results in a dose-dependent decrease in the expression of 
inflammatory mediators which were drastically overexpressed as compared to control. 







Figure 6. MSX treatment results in the decrease of inflammatory mediators associated 
with AD related pro-inflammatory immune cells. Markers of disease associated 
immune cells were significantly reduced in a dose dependent manner with dietary 
supplementation of MSX. Data shown as mean of all biological replicates with 







Figure 7. Treatment with MSX resulted in minimal changes to several 
inflammatory mediators. Several of the proteins analyzed were unaltered or 
minimally altered by MSX treatment. Data shown as mean of all biological replicates 







Figure 8. Treatment with MSX did not alter the expression of AD related 
inflammatory mediators in the cortex. Supplementation of MSX did not result in 
differential expression of inflammatory meditators. Data shown as mean of all 







Figure 9. Proteins highly overexpressed in the cortex showed no changes in expression 
as compared to wild-type mice or with MSX treatment. Data shown as mean of all 







Figure 10. Treatment with MSX did not reduce the expression of pro-inflammatory 
immune cell signatures in the hippocampus. MSX treatment did not result in 
differential expression of inflammatory mediators associated with pro-inflammatory 
immune cells. Data shown as mean of all biological replicates with standard deviation, 





Figure 11. Dietary supplementation with MSX resulted in minimal alterations to the 
expression pattern of several inflammatory mediators in the hippocampus. At this age, 
wild-type mice and 3xTg-AD mice have similar expression patterns in the cortex. 
MSX treatment had minimal effect on this expression pattern. Data shown as mean of 










Humanity has been exploiting the therapeutic and psychoactive effects of natural 
products for thousands of years, however, the idea of drug hunting in natural products 
is a relatively modern idea. Since the conceptualization of modern drug-discovery in 
the early 19th century, natural products have served as the foundation on which many 
medicines are built upon. In the case of Alzheimer’s disease, botanical natural 
products may be particularly helpful in drug discovery efforts. Epidemiological 
evidence suggests that higher dietary intake of botanical natural products, like those 
from fruits, vegetables, and spices, is correlated with lower risk of developing the 
disease. These findings suggest that dietary natural products have compounds intrinsic 
to them which may be useful for the treatment or prevention of Alzheimer’s disease.  
 
However, despite the strong epidemiological evidence, clinical trials aimed at treating 
Alzheimer’s disease with natural products have been unsuccessful. These failures are 
due, in part, to the difficulties of studying the disease. With a long pre-clinical stage, 
rapid cognitive decline in the clinical stage, and poor methods for early detection and 
diagnosis, establishing suitable inclusion/exclusion criteria and outcome measures to 
evaluate a particular drug is a significant challenge. Compounding the difficulty of 
clinical trials is the lack of understanding surrounding the disease biology. For decades 
the main targets of drug discovery efforts were the pathological hallmarks of the 
disease, amyloid plaques, and tau tangles. Despite the strong connection between the 
appearance of these hallmarks and Alzheimer’s disease, therapeutics aimed at these 




paradigm shift in the way Alzheimer’s disease is researched, and thereby treated, is 
needed.      
 
Currently, the Alzheimer’s disease research community is on the brink of this 
paradigm shift. Instead of focusing on targeting and removing the pathological 
hallmarks, the focus is starting to shift to systems ancillary to plaque and tangle 
pathology. One of the main targets is neuroinflammation as it is thought to play a role 
in disease progression. However, the neuroinflammatory response to disease is very 
complex and it is not yet clear which mechanisms should be targeted to produce a 
therapeutic benefit. To overcome this hurdle, a bottom-up approach can be used. 
Instead of taking a critical part of disease biology, identifying a therapeutic 
mechanism, and then exploit that mechanism pharmacologically, the bottom-up 
approach is agnostic to therapeutic mechanism and may in turn discover therapeutic 
mechanisms. One way to go about this approach is to treat animal models of the 
disease that recapitulate the neuroinflammation that has been observed in the human 
condition with extracts of natural products. These extracts would have a diverse 
chemical makeup and therefore, likely act on multiple systems. Changes in 
neuroinflammation can be monitored as outcome measures. Extracts that alter the 
neuroinflammatory phenotype can then be further tested to elucidate the compound or 
compounds responsible for the therapeutic effect, then the mechanisms of action of 
these compounds can be identified. This method allows for the relatively efficient 
screening of dozens of extracts containing several hundreds to even thousands of 
individual constituents. Furthermore, this method may lead to new insights in disease 





This dissertation is the beginning of the bottom-up approach that has established the 
tools and methods required for this approach to be successful. The screening of a large 
library of natural product extracts and pure compounds using wild-type and transgenic 
Caenorhabditis elegans concluded in the identification of several extracts and natural 
products that prolong the lifespan of these models when undergoing stress from a 
toxin or one of the pathological hallmarks of Alzheimer’s disease. Investigations into 
one of these compounds, a gut microbiota metabolite of a natural product, led to the 
discovery of two mechanisms of action which potentially explain the observed 
protective effects against Alzheimer’s disease pathology. And finally, investigations 
into a natural product extract orally dosed in a transgenic mouse model of Alzheimer’s 
disease led to the identification of two efficacious doses that significantly reduce early 
neuroinflammation.     
 
While Alzheimer disease drug discovery has been one of the greatest medical 
challenges to date, recent work has given the research community a more refined 
understanding of disease biology. With these revelations and the failures of many 
major clinical trials focusing on pathological hallmarks of the disease, the field is 
shifting to new hypotheses that may provide more insight into the disease and tractable 
therapeutic routes. Botanical natural products and the gut microbiota metabolites of 
natural products may provide a source of compounds which can be used to evaluate 
several hypotheses and, with more research, be used therapeutically.  
 
